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A B S T R A C T
Background
Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies.
The first-in-class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma,
either as single agent or combined with other therapies.
Objectives
We conducted a systematic review and meta-analysis to assess the effects of bortezomib on overall survival (OS), progression-free survival
(PFS), response rate (RR), health-related quality of life (HRQoL), adverse events (AEs) and treatment-related death (TRD).
Search methods
We searchedMEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE (till 27 January 2016) as well as conference
proceedings and clinical trial registries for randomised controlled trials (RCTs).
Selection criteria
We included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy
in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s) and
iii) bortezomib dose comparisons and comparisons of different treatment administrations and schedules.
Data collection and analysis
Two review authors independently extracted outcomes data and assessed risk of bias. We extracted hazard ratios (HR) and their
confidence intervals for OS and PFS and odds ratios (OR) for response rates, AEs and TRD. We contacted trial authors to provide
summary statistics if missing. We estimated Logrank statistics which were not available. We extracted HRQoL data, where available.
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Main results
We screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta-analyses.
All trials were randomised and open-label studies. Two trials were published in abstract form and therefore we were unable to assess
potential risk of bias in full.
There is moderate-quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92)
and PFS (five studies, 1855 patients; Peto OR 0.65, 95% CI 0.57 to 0.74) from analysing trials of bortezomib versus no bortezomib
with the same background therapy in each arm.
There is high-quality evidence that bortezomib prolongs OS (five studies, 2532 patients; Peto OR 0.76, 95% CI 0.67 to 0.88) but
low-quality evidence for PFS (four studies, 2489 patients; Peto OR 0.67, 95% CI 0.61 to 0.75) from analysing trials of bortezomib
versus no bortezomib with different background therapy in each arm or compared to other agent(s).
Four trials (N = 716) examined different doses, methods of administrations and treatment schedules and were reviewed qualitatively
only.
We identified four trials in the meta-analysis that measured time to progression (TTP) and were able to extract and analyse PFS data
for three of the studies, while in the case of one study, we included TTP data as PFS data were not available. We therefore did not
analyse TTP separately in this review.
Patients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro-intestinal toxicities, peripheral neu-
ropathy, infection and fatigue with the quality of evidence highly variable. There is high-quality evidence for increased risk of cardiac
disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other
agents. The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence.
Only four trials analysed HRQoL and the data could not be meta-analysed.
Subgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for
bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy.
Authors’ conclusions
This meta-analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to
those who did not receive bortezomib. This benefit was observed in trials of bortezomib versus no bortezomib with the same background
therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s).
Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk-benefit profile,
while more studies of HRQoL are also required.
P L A I N L A N G U A G E S U M M A R Y
The role of bortezomib treatment for patients with multiple myeloma
Background
Multiple myeloma is a type of blood cancer, affecting plasma cells inside the bone marrow. Bortezomib is a type of treatment for
myeloma called a proteasome inhibitor. Proteasomes are enzymes found in all cells and play an important role in cell function and
growth. Cancer cells are more sensitive to the effects of bortezomib, causing cancer cells to die or not grow any further.
Study characteristics
We wanted to know the benefits and harms from bortezomib treatment for myeloma. We searched medical databases and trial registries
until January 2016. We included studies of bortezomib compared to no bortezomib, with either the same or different background
therapy or compared to other drugs. Studies of newly diagnosed and relapsed myeloma were included as well as those that compared
different doses, ways of administering bortezomib and treatment schedules.
Key results
We found 16 studies involving 5626 myeloma patients. The results of this review suggest that bortezomib can lead to better survival,
a longer time without progression and better response rates compared to those not receiving bortezomib. Treatment with bortezomib
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causes a number of side effects including: low levels of some blood cells; gastro-intestinal effects such as constipation, diarrhoea, nausea
and vomiting; nerve pain and tingling in hands and feet, as well as infection. A greater risk of heart problems was seen in one of the
comparison groups studied. Risk of death from bortezomib treatment was uncertain in either group analysed. Only four studies assessed
quality of life and could not be analysed together.
Quality of the evidence
We judged quality of the evidence as high to moderate for mortality or number of deaths, whereas it was considered low-quality
evidence for progression-free survival. the quality of evidence for adverse events was highly variable (low to high). For assessment of
treatment-related death, there was no evidence of a difference, with low-quality evidence in one comparison (bortezomib compared
to no bortezomib with the same background therapy) and very low-quality evidence in comparison two (bortezomib compared to no
bortezomib with different background therapy or compared to other drugs).
Conclusion
Patients receiving bortezomib had better response rates, longer time without progression and appeared to live longer compared to those
not receiving bortezomib, however patients receiving bortezomib experienced more side effects. Other proteasome inhibitor drugs have
also been developed, therefore further research should focus on whether these newer drugs provide additional benefits and fewer side
effects than bortezomib. More studies on health-related quality of life are also needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Bortezomib versus no bortezomib
Patient or population: All pat ients with a diagnosis of mult iple myeloma
Setting: Internat ional mult icentre studies
Intervention: Bortezomib
Comparison: Bortezomib versus no bortezomib (same or dif f erent background therapy or other agents)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk without borte-
zomib
Risk with bortezomib
Overall Survival Study populat ion Peto Odds Ratio 0.77
(0.69 to 0.86)
4118
(9 RCTs) HIGH
215 per 1000 166 per 1000
(148 to 185)
Overall Survival - Borte-
zomib versus no borte-
zomib (same back-
ground therapy)
Follow-up 36 to 60
months
Study populat ion Peto Odds Ratio 0.77
(0.65 to 0.92)
1586
(4 RCTs) MODERATE 1
354 per 1000 273 per 1000
(230 to 326)
Overall Survival - Borte-
zomib versus no borte-
zomib (dif f erent back-
ground therapy or other
agents)
Follow-up 7.5 to 67
months
Study populat ion Peto Odds Ratio 0.76
(0.67 to 0.88)
2532
(5 RCTs) HIGH
129 per 1000 98 per 1000
(87 to 114)
Progression-Free Sur-
vival
Study populat ion Peto Odds Ratio 0.67
(0.61 to 0.72)
4344
(9 RCTs) LOW 23
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523 per 1000 350 per 1000
(319 to 377)
Progression-Free Sur-
vival - Bortezomib ver-
sus
no bortezomib (same
background therapy)
Follow-up 30 to 60
months
Study populat ion Peto Odds Ratio 0.65
(0.57 to 0.74)
1855
(5 RCTs) MODERATE 2
324 per 1000 211 per 1000
(185 to 240)
Progression-Free Sur-
vival - Bortezomib ver-
sus no bortezomib (dif -
ferent background ther-
apy or other agents)
Follow-up 22 to 67
months
Study populat ion Peto Odds Ratio 0.67
(0.61 to 0.75)
2489
(4 RCTs) LOW 24
669 per 1000 448 per 1000
(408 to 501)
Treatment-related
death
Study populat ion OR 0.76
(0.43 to 1.34)
2389
(5 RCTs) LOW 6
22 per 1000 17 per 1000
(10 to 29)
Moderate
27 per 1000 21 per 1000
(12 to 36)
Treatment-
related death - Borte-
zomib versus no borte-
zomib (same back-
ground therapy)
Study populat ion OR 0.81
(0.30 to 2.16)
737
(2 RCTs) LOW 6
22 per 1000 18 per 1000
(7 to 47)
Moderate
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35 per 1000 29 per 1000
(11 to 73)
Treatment-related
death - Bortezomib ver-
sus no bortezomib (dif -
ferent background ther-
apy or other agents)
Study populat ion OR 0.73
(0.36 to 1.48)
1652
(3 RCTs) VERY LOW 67
22 per 1000 16 per 1000
(8 to 32)
Moderate
27 per 1000 20 per 1000
(10 to 40)
Health-related quality
of lif e
see comment see comment see comment 717
(4 RCTs)
see comment Each trial used the
same validated qual-
ity of lif e instru-
ment (European Orga-
nizat ion for Research
and Treatment of Can-
cer (EORTC) Quality
of Life Quest ionnaire
(QLQ-C30), whereas the
t ime points of adminis-
trat ion of the quest ion-
naire varied between
the four trials
Adverse Events: Throm-
bocytopenia
Study populat ion OR 2.05
(1.70 to 2.48)
3791
(8 RCTs) LOW 8
114 per 1000 209 per 1000
(180 to 242)
Moderate
48 per 1000 94 per 1000
(79 to 111)
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Adverse Events: Throm-
bocytopenia - Borte-
zomib versus no borte-
zomib (same back-
ground therapy)
Study populat ion OR 1.51
(1.13 to 2.00)
1196
(3 RCTs) HIGH
197 per 1000 271 per 1000
(217 to 330)
Moderate
47 per 1000 70 per 1000
(53 to 90)
Adverse Events: Throm-
bocytopenia - Borte-
zomib versus no borte-
zomib (dif f erent back-
ground therapy or other
agents)
Study populat ion OR 2.60
(2.01 to 3.35)
2595
(5 RCTs) LOW 9
76 per 1000 176 per 1000
(142 to 216)
Moderate
49 per 1000 118 per 1000
(93 to 147)
Adverse Events: Diar-
rhoea
Study populat ion OR 2.44
(1.74 to 3.43)
3788
(8 RCTs) LOW 510
26 per 1000 62 per 1000
(45 to 85)
Moderate
17 per 1000 39 per 1000
(28 to 54)
Adverse Events: Diar-
rhoea - Bortezomib ver-
sus
no bortezomib (same
background therapy)
Study populat ion OR 6.24
(2.79 to 13.98)
1670
(4 RCTs) MODERATE 5
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8 per 1000 50 per 1000
(23 to 106)
Moderate
7 per 1000 41 per 1000
(19 to 87)
Adverse Events: Diar-
rhoea - Bortezomib ver-
sus no bortezomib (dif -
ferent background ther-
apy or other agents)
Study populat ion OR 1.80
(1.22 to 2.65)
2118
(4 RCTs) MODERATE 10
40 per 1000 71 per 1000
(49 to 100)
Moderate
23 per 1000 40 per 1000
(28 to 58)
Adverse Events: Periph-
eral Neuropathy
Study populat ion OR 3.71
(2.92 to 4.70)
4636
(10 RCTs) MODERATE 5
44 per 1000 145 per 1000
(118 to 176)
Moderate
80 per 1000 244 per 1000
(203 to 291)
Adverse Events: Periph-
eral Neuropathy - Borte-
zomib versus no borte-
zomib (same back-
ground therapy)
Study populat ion OR 5.10
(3.37 to 7.72)
2040
(5 RCTs) LOW 510
31 per 1000 139 per 1000
(96 to 196)
Moderate
139 per 1000 453 per 1000
(353 to 556)
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Adverse Events: Periph-
eral Neuropathy - Borte-
zomib versus no borte-
zomib (dif f erent back-
ground therapy or other
agents)
Study populat ion OR 3.09
(2.30 to 4.14)
2596
(5 RCTs) HIGH
54 per 1000 149 per 1000
(116 to 190)
Moderate
21 per 1000 62 per 1000
(47 to 81)
Adverse Events: Infec-
t ions (All)
Study populat ion OR 1.51
(1.27 to 1.79)
4266
(9 RCTs) MODERATE 11
128 per 1000 181 per 1000
(157 to 207)
Moderate
254 per 1000 339 per 1000
(302 to 378)
Adverse Events: Infec-
t ions (All) - Borte-
zomib versus no borte-
zomib (same back-
ground therapy)
Study populat ion OR 1.37
(0.97 to 1.93)
1670
(4 RCTs) HIGH
77 per 1000 103 per 1000
(75 to 139)
Moderate
57 per 1000 77 per 1000
(56 to 105)
Adverse Events: Infec-
t ions (All) - Borte-
zomib versus no borte-
zomib (dif f erent back-
ground therapy or other
agents)
Study populat ion OR 1.55
(1.27 to 1.90)
2596
(5 RCTs) LOW 9
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160 per 1000 228 per 1000
(194 to 265)
Moderate
209 per 1000 291 per 1000
(251 to 335)
Adverse Events: Car-
diac Disorders
Study populat ion OR 1.74
(1.17 to 2.58)
2191
(5 RCTs) HIGH
38 per 1000 65 per 1000
(44 to 93)
Moderate
30 per 1000 51 per 1000
(35 to 74)
Adverse Events: Car-
diac Disorders - Borte-
zomib versus no borte-
zomib (same back-
ground therapy)
Study populat ion OR 1.17
(0.39 to 3.52)
736
(2 RCTs) MODERATE 5
16 per 1000 19 per 1000
(6 to 55)
Moderate
14 per 1000 17 per 1000
(6 to 49)
Adverse Events: Car-
diac Disorders - Borte-
zomib versus no borte-
zomib (dif f erent back-
ground therapy or other
agents)
Study populat ion OR 1.84
(1.21 to 2.81)
1455
(3 RCTs) HIGH
49 per 1000 87 per 1000
(59 to 127)
Moderate
49 per 1000 86 per 1000
(58 to 126)1
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to heterogeneity 55%
2 Downgraded one level because TTP was analysed instead of PFS in one trial.
3 Downgraded one level due to heterogeneity 56%.
4 Downgraded one level due to heterogeneity 70% .
5 Downgraded one level due to low number of events, wide CI.
6 Downgraded two levels due to very low number of events, very wide CI.
7 Downgraded one level due to heterogeneity 53%.
8 Downgraded one level due to heterogeneity 81%.
9 Downgraded one level due to heterogeneity 86%.
10 Downgraded one level due to heterogeneity 57%.
11 Downgraded one level due to heterogeneity 76%.
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B A C K G R O U N D
Description of the condition
Multiple myeloma is a bone marrow-based malignancy charac-
terised by the clonal proliferation of neoplastic plasma cells, the
presence of a monoclonal paraprotein in the blood or urine and
organ dysfunction (Palumbo 2011). An estimated 102,000 people
were diagnosed with myeloma globally in 2008, accounting for
approximately 1% of all cancers diagnosed and 12% of all haema-
tological malignancies (Ferlay 2010). The median age at diagnosis
is approximately 70 years (Palumbo 2011). Recent advances in
treatment have led to significant improvements in relative survival
rates at five and 10 years, improving from 32.8% and 15% in the
period from 1998 to 2002, to 40.3% and 20.8%, respectively, in
the years between 2003 and 2007 (Pulte 2011). Myeloma remains
an incurable condition, however, and therefore the primary goal
of treatment is therefore to control the disease, attain sustainable
remissions and optimise quality of life.
Description of the intervention
Until relatively recently, treatment for myeloma consisted of ei-
ther single agent or combination regimens of chemotherapy drugs
such as melphalan, doxorubicin and vincristine, and the gluco-
corticosteroids, prednisone and dexamethasone (Raab 2009). The
introduction of stem cell transplantation for certain subgroups in
the 1990s led to improvements in disease-free and overall survival
(OS) (Raab 2009). More recently, the development of targeted
therapies such as the immunomodulatory drugs, thalidomide and
lenalidomide, and proteasome inhibitors of which bortezomib was
the first available, has considerably expanded therapeutic options
for myeloma patients (Raab 2009).
The proteasome inhibitor, bortezomib, has been a major advance
in the treatment of myeloma. Bortezomib was first approved for
clinical use based on an overall response rate (ORR) of 35% and a
median time to progression (TTP) of seven months observed in a
phase II trial of patients with relapsed and refractory disease who
were treated with single-agent bortezomib (Richardson 2003). An
international randomised phase III trial evaluating bortezomib
versus high-dose dexamethasone subsequently demonstrated su-
perior response rates, an improved TTP and a superior medianOS
of 29.8 months versus 23.7 months in those receiving bortezomib
(Richardson 2005; Richardson 2007).
A number of trials evaluating bortezomib in combination with
other therapeutic agents have also been reported (Moreau 2012).
Preclinical and clinical data on various combination regimens have
provided support for the hypothesis that bortezomib sensitises
myeloma cells to other therapies, resulting in additive or even
synergistic activity (Shah 2009).
While clinically effective, somemyelomapatients are unable to tol-
erate treatment with bortezomib due to side effects such as nausea,
fatigue, diarrhoea, peripheral neuropathy and thrombocytopenia
(a decreased number of platelets in the blood) (Kyle 2009). Most
of these side effects are predictable and manageable, but in some
cases they may be life-threatening (Bertolotti 2008). Ongoing tri-
als investigating bortezomib in combination with other agents aim
to identify regimens that will provide a more favourable risk-ben-
efit profile (Palumbo 2011).
A number of new ‘second generation’ proteasome inhibitors (carfil-
zomib, marizomib and ixazomib), each with distinct chemical
properties, have also been developed and are undergoing evalua-
tion in clinical trials (Moreau 2012). The most clinically advanced
of these agents is carfilzomib, which was approved for use in pa-
tients withmultiplemyelomawho are progressing on or after treat-
ment with bortezomib and an immunomodulatory agent. This li-
cence was based on a phase II trial of patients with relapsed/refrac-
tory multiple myeloma treated with single agent carfilzomib. An
ORR of 23.7% (95% confidence interval (CI) 18.7% to 29.4%),
a median response duration of 7.8 months and a median OS of
15.6 months was observed (Siegel 2012). It is anticipated, that,
in addition to superior efficacy, these agents will also offer a more
acceptable adverse-event profile compared to bortezomib and will
be clinically useful in patients with myeloma resistant to borte-
zomib (Chen 2011a).
As these newer proteasome inhibitors are still under evaluation,
this review was restricted to the use of bortezomib in the treatment
of myeloma.
How the intervention might work
Bortezomib belongs to a new generation of anti-cancer drugs that
work by targeting specific cell receptors, proteins and signalling
pathways. Proteasomes are 26SATP-dependent protein complexes
within the ubiquitin-proteasome pathway. They are present in all
cells and are responsible for processing themajority of intracellular
proteins (Moreau 2012). Cancer cells generally have higher levels
of proteasome activity when compared with normal cells and are
therefore more sensitive to proteasome inhibition (Moreau 2012),
leading to disruption of cellular growth and survival. This is due to
both the de-regulation of signalling pathways within the myeloma
cell as well as inhibition of the interaction between the myeloma
cells and the bone marrow microenvironment (Chen 2011a).
Bortezomib is a dipeptidyl boronic acid, reversible proteasome
inhibitor that primarily targets the chymotrypsin-like and cas-
pase-like active sites of the proteasome with minimal effect on
trypsin-like activity (Lawasut 2012). Through proteasome inhibi-
tion, bortezomib acts viamultiplemechanisms to suppress tumour
survival pathways and to arrest tumour growth, tumour spread,
and angiogenesis (Moreau 2012).
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Why it is important to do this review
Bortezomib is commonly used for the treatment of myeloma at all
stages of the disease and in all majormyeloma treatment settings. A
systematic review is important to evaluate the accumulated clinical
evidence for the clinical efficacy and tolerability of treatment with
bortezomib.
Randomised controlled trials (RCTs) investigating bortezomib
have demonstrated that its use is associated with statistically sig-
nificant improvements in response rates and event-free survival.
These, however, are primarily surrogate outcomemeasures for OS.
A systematic review and meta-analysis of relevant similar trials will
therefore analyse its effect on OS while analysis of combined data
from similar RCTs will also enable greater precision in making an
unbiased estimate of the effects of treatment.
O B J E C T I V E S
We assessed the effects of bortezomib treatment in comparison
to other therapies, different doses, treatment administration and
schedules of bortezomib, on overall survival (OS), progression-
free survival (PFS), response rate (RR), health-related quality of
life (HRQoL), adverse events (AE) and treatment-related death
(TRD).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in which the in-
tervention consisted of bortezomib for the treatment of myeloma.
Types of participants
Patients of any age, gender or ethnic origin and with any diagno-
sis of multiple myeloma (according to either the Durie-Salmon
staging system or International Staging System (ISS) (Kyle 2009)
were included in this review.We included patients who were either
newly diagnosed (had received no prior therapy) or patients with
relapsed disease. We also included patients who were considered
to be either transplant eligible or ineligible. Patient eligibility for
stem cell transplant is determined primarily by age, as well as per-
formance status, frailty, and presence of comorbidities. We did not
define transplant eligibility for this review and therefore selected
studies that included all types of patients.
Types of interventions
We included RCTs that investigated the following comparisons.
• Bortezomib versus no bortezomib with the same
background therapy in each arm
• Bortezomib versus no bortezomib with different
background therapy in each arm or compared to other agent(s)
• Bortezomib dose comparisons and comparisons of different
treatment administrations and schedules
We combined two of the comparison groups (studies of borte-
zomib versus no bortezomib with different background therapy
in each arm and studies of bortezomib versus other agents(s)) as
these studies included complex combination regimens/therapies,
with some studies considered as belonging to either comparison.
Types of outcome measures
Primary outcomes
• Overall survival (OS): time from date of randomisation to
date of death (from any cause)
• Progression-free survival (PFS): time from date of
randomisation to date of progression or death (from any cause)
Secondary outcomes
• Overall response rate (ORR), complete response rate
(CRR) and partial response rate (PRR): the proportion of
patients with overall, complete or partial response
• Time to progression (TTP): time from randomisation to
date of progression. As TTP may also be referred to as PFS, we
planned to only analyse TTP separately, if it were defined
differently
• Treatment-free interval (TFI): time from randomisation to
date of initiation of next treatment regimen or similar
• Treatment-related death: death due to treatment-related
toxicity and not disease progression
• Adverse events (AE): as defined by the National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE)
• Health-related quality of life (HRQoL): as defined by the
validated quality of life measures or instruments used in each trial
Search methods for identification of studies
Electronic searches
We performed a systematic search of the following electronic
databases, using comprehensive search strategies incorporating key
search terms.
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• The Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library) till 27 January 2016
(Appendix 1)
• MEDLINE (Ovid) till 27 January 2016 (Appendix 2)
• EMBASE (Elsevier) till 31 July 2015 (Appendix 3)
Databases were searched using the Cochrane Highly Sensitive
Search Strategy (Lefebvre 2011) to identify randomised trials in
MEDLINE combined with selected MeSH terms and free text
terms. Language restrictions were not imposed. Search strate-
gies were tailored to the other databases. The search strategies for
databases are shown in Appendix 1, 2 and 3.
Electronic searches of MEDLINE and CENTRAL were con-
ducted by theCHMGTrial Search Co-ordinator and of EMBASE
by the first author of the review with support from a librarian.
Results of the electronic databases were collated into a single ref-
erence library using the reference manager software Endnote X6
(EndNote 2012) and independently screened by two review au-
thors (KS and AH).
Searching other resources
In addition, we searched for ongoing and unpublished clinical tri-
als in the following clinical trial registries using key words ‘borte-
zomib’, ‘multiple ‘myeloma’ and ‘randomised’:
• National Institute of Health (NIH) Register http://
clinicaltrials.gov (search date: 04 May 2015)
• International Standard Randomised Controlled Trial
Number (ISRCTN) register http://www.controlledtrials.com
(search date: 04 May 2015)
We searched also online archives of conference proceedings for
relevant meeting abstracts:
• American Society of Hematology (ASH) 2012 to 2015
• American Society of Clinical Oncology (ASCO) 2012 to
2015
• European Hematology Association (EHA) 2012 to 2015
• European Society of Medical Oncology (ESMO) 2011 to
2015
We also searched reference lists of relevant studies and review arti-
cles and contacted principal investigators and trial sponsors by e-
mail regarding status of unpublished or incomplete trials.
Data collection and analysis
Selection of studies
Two review authors (KS and AH) independently screened the ab-
stracts of retrieved articles for eligibility according to pre-deter-
mined criteria. Any inconsistencies between the review authors
during the screening process were discussed. If a decision could not
be made on the basis of the abstract, a full-text article of the study
in question was retrieved and assessed independently by the two
authors to make the final decision regarding study eligibility. No
articles or studies required discussion with a third review author.
The number of studies identified, the number of included and
excluded studies and reasons for inclusion/exclusion were docu-
mented according to PRISMA guidelines (Moher 2009).
Data extraction and management
For each eligible trial, two review authors (KS and AH) indepen-
dently extracted data using a data extraction form, which included
the following.
• Trial identification: title, authors, journal name, publication
date, countries, sponsor, funding
• Trial design: type of trial design, treatment setting, number
of arms, number of centres, sample size and rationale,
randomisation method, allocation concealment, blinding,
stratification factors, analysis methods, pre-specified alpha error,
beta error, effect size, analysis types (e.g. intention-to-treat
(ITT), per protocol)
• Trial comparisons: Experimental and control arms, number
of courses of treatment, doses, timing and route of
administration, other treatments received
• Trial participants: age (median/mean and age range), sex,
stage (Durie-Salmon, International or both), inclusion criteria,
exclusion criteria
• Trial progress and follow-up: duration of accrual and
follow-up periods, number of participants per arm, number of
participants lost to follow-up, and excluded from analysis
• Outcomes:
◦ Overall survival (OS)
◦ Progression-free survival (PFS)
◦ Overall response rate (ORR); complete response rate
(CRR); partial response rate (PRR)
◦ Time to progression (TTP)
◦ Treatment-free interval
◦ Treatment-related death (TRD)
◦ Adverse events (AEs)
◦ Health-related quality of life (HRQoL)
Review author KS entered data into the Characteristics of Studies
tables in RevMan and AH checked these tables for accuracy. AH
entered the outcomes data intoRevMan andKS checked these data
for accuracy. Any inconsistencies or disagreements were resolved
through discussion between the two authors.
For studieswithmore thanone publication,we extracted data from
all publications as per recommendations provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a),
however we considered the final or updated version of each trial
as the primary source for the extraction of outcomes data.
For studies with a 3-arm randomisation, data were extracted for
just the unconfounded comparison (bortezomib versus no borte-
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zomib with the same background therapy) in that randomisation,
or by grouping arms containing bortezomib.
Assessment of risk of bias in included studies
We used the Rrisk of bias’ assessment tool as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b), and classified trials at low, high or unclear risk of bias for
the following.
• Random sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants (performance bias)
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Other sources of bias.
For each type of bias, a judgement was made using one of three
categories:
• low risk: if the criterion was adequately fulfilled;
• high risk: if the criterion was not fulfilled;
• unclear risk: if the report did not provide sufficient
information to allow for a judgement of high or low risk or if the
risk of bias is unknown.
We assessed individual outcomes e.g. OS, RR according to the
above criteria (see Characteristics of included studies and ’Risk of
bias’ tables).
Measures of treatment effect
• Time-to-event outcomes data: We extracted the hazard
ratios (HR) and 95% confidence intervals (CI) for OS and PFS
from included studies and calculated the overall odds ratio (OR)
and 95% CI for combined studies using methods recommended
in theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a).
• Dichotomous outcomes data
◦ Response and progression of disease were reported in
each included trial according to either the International Myeloma
Working Group (IMWG) uniform response criteria or European
Group for Blood and Bone Marrow Transplantation (EBMT)
criteria (Kyle 2009). The IMWG uniform response criteria were
developed similarly to the EBMT criteria with some notable
modifications (Kyle 2009). For the purposes of this review and
meta-analysis, we assumed that complete response (CR) and
overall response were similar regardless of the response criteria
used. We extracted the CRR and ORR as reported in each trial
and analysed these data as odds ratios (OR) with 95% CIs.
◦ AEs were reported in each included trial according to
the National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE). AEs may occur more than once in
the same individual, particularly during different treatment
cycles. The number of grade 3/4 AEs were reported as a
percentage (%) of the total number of patients on each arm in
each included trial. Therefore, we assumed that each AE was
counted once and analysed these data as dichotomous data.
◦ Treatment-related deaths were extracted from the text
of the trial publication where reported and analysed as
dichotomous data.
• Continuous outcomes data: We planned to extract HRQoL
data where this was reported as an outcome measure. A variety of
quality of life measurement instruments may be used and may
also be measured at differing time points. We could not conduct
meta-analysis due to variation in reporting and incomplete data
and therefore we summarised these data only.
Unit of analysis issues
We did not anticipate any unit of analysis issues.
Dealing with missing data
We approached dealing with missing data according to recom-
mendations provided in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011a) and classified data as either
’missing at random’ or ’not missing at random’. In the case of data
considered to bemissing at random,we analysed the available data.
For data considered to be not missing at random, we contacted
the trial authors for further information.
If data were still not available, we stated the assumptions made
for the analysis. Logrank statistics that were not available from the
published articles were estimated. Where possible we used previ-
ously reported methods (Parmar 1998; Tierney 2007). The meth-
ods followed and estimates made were verified by an independent
statistician. In one case (MD Anderson Study), original data were
recreated based on the Kaplan-Meier plot.
Assessment of heterogeneity
The presence of statistical heterogeneity of included studies was
assessed using the Chi2 test at a significance level of P < 0.10
(Deeks 2011). The I2 statistic was used to quantify heterogeneity
according to the following thresholds described in theCochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011):
• 0% to 40% (heterogeneity possibly not important);
• 30% to 60% (may represent moderate heterogeneity);
• 50% to 90% (may represent substantial heterogeneity);
• 75% to 100% (considerable heterogeneity).
Where we identified heterogeneity, we conducted subgroup anal-
yses as outlined in the section Subgroup analysis and investigation
of heterogeneity.
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Assessment of reporting biases
To assess the likelihood of reporting bias, funnel plots were pro-
duced according to methods described in the Cochrane Handbook
for Systematic Reviews of Interventions (Sterne 2011). This was done
for the primary outcomes only.
Data synthesis
We used the latest version of the software package RevMan 5.3
(RevMan 5.3) to enter data and combined results from included
studies.
Standard statistical methods for themeta-analysis of dichotomous,
time-to-event and continuous variables were used. If time-to-event
outcomes were not available, we calculated summary estimates.
Fixed-effect methods for meta-analysis were utilised. TheO-E and
V method was used to calculate the effect size, a commonly used
method in meta-analysis which produces a Peto odds ratio (OR)
rather than a Hazard Ratio (HR). In some cases, the published
HR was used to calculate O-E and V, and therefore the Peto OR
obtained was the same as the HR; if the HR was not available, the
statistics were estimated from other data provided (e.g. P value and
number of events). This method was therefore used to estimate
the effect size when a publication did not adequately report the
HR and CIs.
We produced a ’Summary of findings’ table using GRADE soft-
ware (Schünemann 2011) and summarised the results forOS, PFS,
TRD, HRQoL and major AEs. We pooled results where the data
were sufficiently similar to be combined and performed a meta-
analysis for each comparison. We analysed comparisons 1 and 2
together and comparison 3 was analysed qualitatively only.
Subgroup analysis and investigation of heterogeneity
We analysed the following subgroups.
Disease setting
• Newly diagnosed (transplant eligible)
• Newly diagnosed (transplant ineligible)
• Relapsed and/or relapsed/refractory
Therapy setting
• Induction therapy (pre-transplant)
• Consolidation therapy (post-transplant)
• Maintenance therapy (post-transplant)
Tests for heterogeneity were used to investigate whether the treat-
ment effect was greater in some subgroups than in others. Tests
for interactions were used to verify subgroup differences.
Where a trial used bortezomib in more than one therapy setting,
it was included in all relevant subgroups. Consequently only sub-
group totals and no overall totals were calculated for these analy-
ses.
Sensitivity analysis
We did not conduct a sensitivity analysis excluding trials consid-
ered to be at an overall high risk of bias (see Differences between
protocol and review).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Ongoing studies.
Results of the search
The primary electronic searches of each database (CENTRAL,
MEDLINE, and EMBASE) performed in January 2016 yielded
a total of 33761 records after the removal of internal duplicates.
Results from each database were collated into a single EndNote
library, with additional duplicates removed, leaving 3667 records
in total to be screened according to the eligibility criteria. A to-
tal of 3382 records were excluded as irrelevant. Reasons for ex-
clusion included: non-clinical studies; clinical studies unrelated to
bortezomib and/or multiple myeloma; non-randomised studies,
retrospective studies or case studies. Sixteen additional duplicate
records were also removed and 55 records were considered to be
not the definitive articles. The remaining 38 records were then
sourced in full text for more detailed evaluation. A further 12
records were excluded at this stage.
Sixty-four additional records were identified through other sources
from the screening of conference proceedings, clinical trials reg-
istries, checking of reference lists of relevant studies and review ar-
ticles and handsearching. One full-text article that was identified
through handsearching was added after the date of the electronic
searches as it provided relevant updated outcomes data for one of
the included trials (GIMEMA-MM-03-05 Study).
At least three trials were identified as completed in 2013 through
searches of clinical trials registries (Consolidation (61-75 years)
Study; Consolidation (less than 60 years) Study; King Fasail
Hospital Study), however these trials are not yet published in full
and no further data have been made available.
Finally, a total of 16 studies were considered eligible for inclusion
and a total of six studies excluded. The process and results of
study identification are outlined in a flow diagram according to
the PRISMA statement (Moher 2009) (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The number of included trials according to our eligibility crite-
ria is 16 trials involving 5626 patients. The characteristics of the
included studies are summarised in the table Characteristics of
included studies.
Among these trials, six trials involving 2247 patients evaluated
bortezomib versus no bortezomib with the same background ther-
apy in each arm (GEM05MENOS65 Study; GIMEMA-MMY-
3006 Study;MDAnderson Study;MMVAR/IFM2005-04 Study;
NMSG 15/05 Study; VISTA Study). Another six trials involving
2663 patients evaluated bortezomib versus no bortezomib with
either different background therapy in each arm or compared to
other agents (All India Institute Study; APEX Study; GIMEMA-
MM-03-05 Study; HOVON-65/GMMG-HD4 Study; IFM
2005-01 Study; NMSG 17/07 Study). Meta-analyses were per-
formed on these two groups of trials (12 trials in total).
Finally, four trials involving 716 patients assessed bortezomib dose
comparisons, methods of administrations and treatment schedules
(CREST Study; GEM2010MAS65 Study; IFM 2007-02 Study;
MMY-3021 Study). The trials in this group were too dissimilar
for meta-analysis. These trials were therefore assessed qualitatively
only.
Design
All trials included in this review were randomised and open-
label. The majority of trials were two-armed randomised
controlled trials (RCTs), while two trials were three-armed
RCTs (GEM05MENOS65 Study; MD Anderson Study) and
one trial was a four-arm RCT (IFM 2005-01 Study). The
GEM05MENOS65 Study randomised patients to one of three
induction therapy arms (Arm A (VTD: bortezomib, thalido-
mide, dexamethasone), Arm B (TD: thalidomide, dexametha-
sone), and Arm C (VBMCP/VBAD/B: vincristine, BCNU, mel-
phalan, cyclophosphamide, prednisone/vincristine, BCNU, dox-
orubicin, dexamethasone/bortezomib). Following completion of
stem cell transplantation, eligible patients were randomised a sec-
ond time to one of three maintenance arms: Arm A (TV: thalido-
mide, bortezomib, Arm B (T: thalidomide only), and Arm C
(alfa2-IFN: Interferon alpha-2b). We extracted data for two arms
only i.e. VTD versus TD alone in the induction phase andTV ver-
sus T in the maintenance phase, as the third arm was confounded
by the administration of other therapies. In the MD Anderson
Study, patients were randomised in a 1:1:1 ratio to one of three
arms (20 patients per group): the conditioning regimen with no
bortezomib (Group 1), the conditioning regimen and 1 mg/m2 of
bortezomib (Group 2) or the conditioning regimen and 1.5mg/
m2 of bortezomib (Group 3). We combined the extracted data
from Groups 2 and 3 for the meta-analysis and we re-created the
original data from the published Kaplan-Meier plots. In the case
of the IFM 2005-01 Study, patients were randomised to receive
vincristine Adriamycin dexamethasone (VAD) induction, with or
without dexamethasone, cyclophosphamide, etoposide and cis-
platin (DCEP) consolidation or bortezomib and dexamethasone
(BD) induction, with or without DCEP consolidation and we
were therefore able to combine data as a two-arm comparison.
Sample sizes
The smallest trial had a sample size of 43 patients (All India
Institute Study), while the largest trial was the HOVON-65/
GMMG-HD4 Study with a sample size of 827 patients.
Setting
The majority of trials were multi-centre trials conducted ei-
ther within a single country or in several countries. Two trials
were conducted in single centres only (MD Anderson Study; All
India Institute Study). Seven trials were conducted in newly di-
agnosed transplant eligible patients (GEM05MENOS65 Study;
GIMEMA-MMY-3006 Study; HOVON-65/GMMG-HD4
Study; IFM 2005-01 Study; IFM 2007-02 Study; MD Anderson
Study; NMSG 15/05 Study), three trials in transplant ineligi-
ble patients (GIMEMA-MM-03-05 Study; GEM2010MAS65
Study; VISTA Study), and five trials in patients with relapsed/re-
fractory myeloma (APEX Study; CREST Study; MMVAR/IFM
2005-04 Study; MMY-3021 Study; NMSG 17/07 Study). One
trial studied myeloma patients with light chain induced acute re-
nal failure (All India Institute Study).
Participants
All trials included male and female patients with a diagnosis of
multiple myeloma according to either the Durie-Salmon staging
system or International Staging System (ISS) and who were at least
18 years of age. Upper age limits were reported in some trials;
patients less than 65 years of age were included in transplant eligi-
ble trials, whereas patients greater than 65 years were included in
transplant ineligible trials. We did not extract or analyse age be-
cause of the variation across trials and instead conducted subgroup
analysis of trials of transplant eligible and ineligible patients.
Interventions
Interventions included bortezomib in combination with other
agents, such as chemotherapy drugs e.g. cyclophosphamide, mel-
phalan; corticosteroids e.g. dexamethasone and prednisone and
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immuno-modulatory agents e.g. thalidomide and included two-
, three- and four-drug combinations, given orally and/or by in-
travenous administration, or both. Bortezomib as a single agent
was evaluated in four trials (APEX Study; CREST Study; NMSG
15/05 Study; MMY-3021 Study). The APEX Study compared
bortezomib and high-dose dexamethasone with high-dose dex-
amethasone only in patients with relapsed disease who had re-
ceived one to three prior therapies. In this study 62% of patients
on the high-dose dexamethasone arm crossed over to the borte-
zomib arm following disease progression. The CREST Study was
the first published randomised study of bortezomib to evaluate
the safety and efficacy of two doses of bortezomib in 54 patients
who had relapsed after or were refractory to frontline therapy and
received intravenous bortezomib at doses of 1.0 mg/m2 or 1.3
mg/m2 twice weekly for two weeks every three weeks for up to
eight cycles. The MMY-3021 Study was a non-inferiority trial
that compared subcutaneous versus intravenous administration
of bortezomib, while the NMSG 15/05 Study evaluated borte-
zomib as consolidation therapy versus no treatment. Interven-
tions including bortezomib were administered as induction ther-
apy (prior to stem cell transplantation) in five trials, of which
two trials also includedmaintenance therapy (GEM05MENOS65
Study; HOVON-65/GMMG-HD4 Study) and one trial included
consolidation therapy (GIMEMA-MM-03-05 Study) post-trans-
plant. One trial evaluated maintenance therapy in transplant in-
eligible patients (GIMEMA-MM-03-05 Study). Comparator(s)
included either: no therapy, chemotherapy drugs, corticosteroids
and/or combination treatment regimens.
Outcomes
Overall survival (OS) and progression-free survival (PFS) data
were available from nine trials (APEX Study; GIMEMA-MM-03-
05 Study; GIMEMA-MMY-3006 Study; HOVON-65/GMMG-
HD4 Study; IFM 2005-01 Study; MD Anderson Study;
MMVAR/IFM 2005-04 Study; NMSG 15/05 Study; VISTA
Study). Time to progression (TTP) was reported in four tri-
als (APEX Study; GIMEMA-MMY-3006 Study; MMVAR/IFM
2005-04 Study; VISTA Study). Treatment-free interval (TFI) or
time to next treatment or therapy was reported in two trials
(NMSG 17/07 Study; VISTA Study). Response rates were re-
ported in all trials, although not all response categories (overall,
complete and partial response) were reported, therefore we priori-
tised the extraction and analysis of overall response rate (ORR)
and complete response rate (CRR) data. Adverse events (AEs) were
also reported in all trials, although the level of AE reporting varied.
We therefore prioritised the extraction and analysis of common
grade 3 and grade 4 AEs. Treatment-related deaths (TRD) were
reported in five trials (APEXStudy;GIMEMA-MM-03-05 Study;
IFM 2005-01 Study; MD Anderson Study; VISTA Study), while
four trials included health-related quality of life (HRQoL) out-
comes (APEX Study, NMSG 15/05 Study, NMSG 17/07 Study
and VISTA Study).
See Characteristics of included studies for further details.
Excluded studies
A total of six studies were excluded (Characteristics of excluded
studies). The study by Chen 2011b compared bortezomib and
dexamethasone (BD) versus vincristine, doxorubicin and dexam-
ethasone (VAD) as induction therapy followed by thalidomide as
maintenance therapy in newly diagnosed myeloma. The study de-
sign was described as ’retrospective randomised’ involving 46 pa-
tients that were randomised according to date of hospitalisation.
We decided to exclude this study as it was a small study incorpo-
rating a quasi-randomisation method. The remaining five studies
were excluded because each trial involved bortezomib treatment
at the same dose or schedule on both arms.
Risk of bias in included studies
Results of the overall ’Risk of bias’ assessment is presented in Figure
2 and a summary of the risk of bias for each included trial is
presented in Figure 3. Some criteria are assessed for individual
outcomes e.g. blinding, intention-to-treat (ITT) analysis.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
20Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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The funnel plots for the primary outcomes of OS and PFS did
not suggest publication bias.
Allocation
We judged the potential risk of selection bias for random sequence
generation as low for most included trials with the exception of
one trial (All India Institute Study). This study was published as a
conference abstract and was described as ’randomised’ in the title,
however provided no additional information regarding randomi-
sation. All other trial publications provided a clearer description
of randomisation and therefore we considered these trials to be at
low risk of bias for random sequence generation.
We judged the potential risk of bias as low for allocation conceal-
ment for nine of the included trials, as the type of randomisation
system used was adequately reported e.g. centrally randomised or
web-based system, whereas the potential risk of bias for seven tri-
als was considered to be as unclear as no details were provided.
One trial used randomisation envelopes, and was judged to be at
somewhat higher risk of bias (CREST Study). However, this was
still allocated low risk as per Cochrane guidelines.
Blinding
All trial allocations were open-label, with both participants and
trial personnel aware of the treatments administered. Blinding in
cancer trials poses ethical considerations and is generally difficult
to implement because of the different adverse-event profiles, routes
of administration and schedules between treatment arms. Open-
label studies are more susceptible to performance bias, therefore
we judged the potential risk of bias for blinding of participants
and personnel to be high.
Blinding of outcomes assessment was employed in 10 of the 16
trials, wherein outcomes were assessed independently e.g. disease
response assessment performed by central laboratory analysis and/
or results adjudicated by an independent committee of experts or
data analysts. We therefore considered these trials to be at low risk
of detection bias for outcome assessment. For the remaining six
trials, we considered the risk of detection bias as unclear as these
trials did not report the use of central or independent review of
outcomes data.
Incomplete outcome data
We judged the potential risk of attritionbias as low for the included
trials with the exception of the GEM2010MAS65 Study. This
study has only been published as a conference abstract to date,
therefore did not provide sufficient information to fully assess
this criterion. We considered the potential risk of attrition bias
as unclear. It was noted that this trial is ongoing at the time of
preparing this review. The majority of trials provided a detailed
participant flow chart with the rates of withdrawal, drop-out and
loss to follow-up being generally acceptable and the completeness
of follow-up data considered adequate.
Selective reporting
We judged the risk of reporting bias as low in 12 of the 16 tri-
als as the benefits and side effects of treatment were adequately
reported for each arm. We considered the risk of reporting bias
as unclear for three trials. Two trials reported selected AEs only
(GEM05MENOS65 Study and NMSG 15/05 Study), while one
trial has only been published as a conference abstract and did not
have sufficient information available (GEM2010MAS65 Study).
It was noted that this trial is registered on a clinical trials registry
and is ongoing at the time of preparing this review. We considered
one trial to be at high risk of reporting bias (All India Institute
Study). This trial was also published as a conference abstract and
did not report the key eligibility criteria or details of baseline char-
acteristics in each arm. Selected AEs were reported. We could not
find this trial registered on a clinical trials registry and we were
unable to contact the study authors.
It was noted that 14 of the 16 trials were registered on a publicly
accessible clinical trials registry. There were two exceptions (All
India Institute Study and CREST Study). The latter study was
conducted in 2001 when registration was not yet routine and may
have not been registered for this reason. The number of relevant
trials identified through searches of clinical trials registries were
in line with that conducted at the protocol stage of this review
(preliminary searches were conducted in 2012 and in 2013).
Other potential sources of bias
Wedid not identify any other potential sources of bias in the 16 tri-
als.We extracted sponsorship and fundingdetails for each included
trial where it was reported and did not identify any particular bias
regarding either of these sources. It was noted that four of the 16
trials were sponsored by pharmaceutical companies (APEX Study;
CREST Study; MMY-3021 Study; VISTA Study), while 11 tri-
als were sponsored either by academic groups, research institutes,
hospitals or investigators and one trial’s sponsorship was unknown
(All India Institute Study). Four trials sponsored by academic
groups reported sources of funding from pharmaceutical compa-
nies (GEM05MENOS65 Study; GIMEMA-MMY-3006 Study;
HOVON-65/GMMG-HD4 Study; MD Anderson Study).
Effects of interventions
See: Summary of findings for the main comparison Bortezomib
versus no bortezomib for the treatment of multiple myeloma
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See Summary of findings for the main comparison for the main
comparisons.
Comparison 1 and 2: Bortezomib versus no
bortezomib with the same background therapy in
each arm/bortezomib versus no bortezomib with
different background therapy in each arm or
compared with other agent(s)
Primary Outcomes
Overall survival (OS)
We estimated OS from nine of 12 trials (All India Institute Study;
APEX Study; GIMEMA-MM-03-05 Study; GIMEMA-MMY-
3006 Study; HOVON-65/GMMG-HD4 Study; IFM 2005-01
Study;MDAnderson Study;NMSG15/05 Study; VISTA Study).
We included a total of 4118 patients with 821 reported deaths.
Two studies (All India Institute Study; IFM 2005-01 Study) re-
ported the number of events (number of deaths) per arm, however
the publications did not include a Hazard Ratio (HR) comparing
the treatments with either a corresponding P value or a 95% con-
fidence interval (CI) for the outcome of OS and therefore were
considered non-estimable for the pooled estimate. The Peto odds
ratio (OR) is 0.77 (95%CI 0.69 to 0.86, P < 0.00001) in favour of
bortezomib (Analysis 1.1) (Figure 4). In the comparison of borte-
zomib versus no bortezomib with the same background therapy
in each arm, an analysis of 1586 patients produced a statistically
significant OS benefit (Peto OR = 0.77 (95% CI 0.65 to 0.92,
P < 0.00001) for patients receiving bortezomib. The comparison
of bortezomib versus no bortezomib with different background
therapy in each arm or compared to other agent(s) included 2532
patients and produced a statistically significant OS benefit (Peto
OR = 0.76 (95% CI 0.67 to 0.88, P < 0.00001) for patients re-
ceiving bortezomib. Moderate heterogeneity was observed in the
studies of bortezomib versus no bortezomib with the same back-
ground therapy (I2 = 55%), while no heterogeneity was observed
in the studies of different background therapy or when compared
to other agents (I2 = 0%), resulting in minor heterogeneity across
both groups (I2 = 18%). The test for subgroup differences was
not significant (P = 0.92). This meta-analysis indicates that there
is evidence of a significant beneficial effect upon OS in favour of
bortezomib.
Figure 4. Forest plot of comparison: 3 All studies, outcome: 3.1 Overall Survival.
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Progression-free (PFS) survival
We estimated PFS fromnine of 12 trials (APEX Study;GIMEMA-
MM-03-05 Study; GIMEMA-MMY-3006 Study; HOVON-65/
GMMG-HD4 Study; IFM 2005-01 Study;MDAnderson Study;
MMVAR/IFM 2005-04 Study; NMSG 15/05 Study; VISTA
Study). We included a total of 4344 patients and an estimated
2063 progression events. The Peto OR is 0.67 (95% CI 0.61 to
0.72, P < 0.00001) in favour of bortezomib (Analysis 1.2) (Figure
5). In the comparison of bortezomib versus no bortezomib with
the same background therapy in each arm, an analysis of 1855
patients produced a statistically significant PFS benefit (Peto OR
= 0.65 (95% CI 0.57 to 0.74, P < 0.00001) for patients receiving
bortezomib. The comparison of bortezomib versus no bortezomib
with different background therapy in each arm or compared to
other agent(s) included 2489 patients and produced a statistically
significant PFS benefit (PetoOR = 0.67 (95%CI 0.61 to 0.75, P <
0.00001) for patients receiving bortezomib.Moderate heterogene-
ity was observed in the studies of bortezomib versus no bortezomib
with the same background therapy (I2 = 49%), while substantial
heterogeneity was observed in the other comparison group (I2 =
70%), resulting in moderate heterogeneity across both groups (I
2 = 56%). The test for subgroup differences was not significant
(P = 0.68). This meta-analysis indicates that there is evidence of a
significant beneficial effect upon PFS for bortezomib.
Figure 5. Forest plot of comparison: 3 All studies, outcome: 3.2 Progression Free Survival.
Secondary Outcomes
Complete response rate (CRR)
We estimated CRR from 12 trials. We included a total of 4630
patients with 1093 complete responses.The odds ratio (OR) is
2.35 (95% CI 2.02 to 2.73, P < 0.00001) in favour of bortezomib
(Analysis 1.3) (Figure 6). In the comparison of bortezomib versus
no bortezomib with the same background therapy in each arm, an
analysis of 2064 patients produced a statistically significant benefit
for CRR (OR = 2.63 (95% CI 2.13 to 3.24, P < 0.00001) for pa-
tients receiving bortezomib. The comparison of bortezomib versus
no bortezomib with different background therapy in each arm or
compared to other agent(s) included 2566 patients and produced
a statistically significant benefit for CRR (OR = 2.08 (95% CI
1.67 to 2.58, P < 0.00001) for patients receiving bortezomib. Sub-
stantial heterogeneity was observed in the studies of bortezomib
versus no bortezomib with the same background therapy (I2 =
86%), and moderate heterogeneity observed in the studies of dif-
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ferent background therapy or when compared to other agents (I2
= 53%), resulting in substantial heterogeneity across both groups
(I2 = 77%). The test for subgroup differences was not significant
(P = 0.13). This meta-analysis indicates that there is evidence of a
significant beneficial effect upon CRR in favour of bortezomib.
Figure 6. Forest plot of comparison: 3 All studies, outcome: 3.3 Complete Response Rate.
Overall response rate (ORR)
We estimated ORR from 12 trials. We included a total of 4630
patients with 3311 overall responses. The OR is 2.62 (95% CI
2.25 to 3.05, P < 0.00001) in favour of bortezomib (Analysis 1.4)
(Figure 7). In the comparison of bortezomib versus no bortezomib
with the same background therapy in each arm, an analysis of
2064 patients produced a statistically significant benefit for ORR
(OR = 3.45 (95% CI 2.72 to 4.37, P < 0.00001) for patients
receiving bortezomib. The comparison of bortezomib versus no
bortezomib with different background therapy in each arm or
compared to other agent(s) included 2566 patients and produced a
statistically significant benefit for ORR (OR = 2.17 (95% CI 1.78
to 2.64, P < 0.00001) for patients receiving bortezomib. Moderate
heterogeneity was observed in the studies of bortezomib versus no
bortezomib with the same background therapy (I2 = 44%), and
no heterogeneity observed in the other comparison group (I2 =
0%), resulting in moderate heterogeneity across both groups (I2 =
52%). The test for subgroup differences was significantly different
(P = 0.00). The direction of treatment effect, however, favoured
bortezomib in both groups. Thismeta-analysis indicates that there
is evidence of a significant beneficial effect upon ORR in favour
of bortezomib.
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Figure 7. Forest plot of comparison: 3 All studies, outcome: 3.4 Overall Response Rate.
Time to progression (TTP)
We identified four trials in the meta-analysis that measured TTP
as an outcome (APEX Study; GIMEMA-MMY-3006 Study,
MMVAR/IFM 2005-04 Study; VISTA Study). We were able to
extract and analyse PFS data for the VISTA Study, GIMEMA-
MMY-3006 Study and MMVAR/IFM 2005-04 Study, while in
the case of the APEX Study, we included TTP data as PFS data
were not available. We therefore did not analyse TTP separately.
Treatment-free interval (TFI)
Treatment-free interval (TFI) or time to next treatment or ther-
apy was reported in two of 16 trials (NMSG 17/07 Study; VISTA
Study). Each trial belonged to different comparison groups, there-
fore it was not possible to conduct meta-analysis on this outcome.
In the NMSG 17/07 Study, patients were randomised to borte-
zomib and dexamethasone (BD) or thalidomide and dexametha-
sone (TD) and assessed the time to start of next line of treatment
which was similar for both groups (median of 8.5 months (95%
CI 4.5 to 11.8) for BD and 9.7 months (95% CI 5.3 to 11.4) for
TD). In the VISTA Study, patients were randomised to receive
bortezomib, melphalan and prednisone (VMP) or melphalan and
prednisone (MP) alone. The TFI was significantly longer in the
bortezomib group than in the control group (median 19.4 versus
9.1 months, HR = 0.573, P = 0.001).
Treatment-related death (TRD)
We estimated TRD from five of 12 trials. We included a total of
2389 patients with 46 TRDs. The OR is 0.76 (95% CI 0.43 to
1.34, P = 0.34) (Analysis 1.5). In the comparison of bortezomib
versus no bortezomib with the same background therapy in each
arm, only two trials were included, with no statistically significant
difference between the groups (OR = 0.81 (95% CI 0.30 to 2.16,
P = 0.67). The comparison of bortezomib versus no bortezomib
with different background therapy in each arm or compared to
other agent(s) included three trials and also produced a non-sta-
tistically significant difference between the groups (OR = 0.73
(95% CI 0.36 to 1.48, P = 0.12). Minor heterogeneity was ob-
served in the studies of bortezomib versus no bortezomib with the
same background therapy (I2 = 9%), and moderate heterogene-
ity observed in the other comparison group (I2 = 53%), resulting
in low heterogeneity across both groups (I2 = 24%). The test for
subgroup differences was not significant (P = 0.87). This meta-
analysis indicates that there is no significant difference in TRD
between bortezomib and bortezomib-containing therapies versus
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non-bortezomib containing control groups.
Adverse events (AEs)
Thrombocytopenia
Eight of the 12 trials reported on the frequency of grade three or
four thrombocytopenia. There were 380 cases (20.0%) in 1897
patients in the bortezomib group and 216 cases (11.4%) in 1894
patients in the control group. The increased risk of thrombocy-
topenia in patients treated with bortezomib was statistically sig-
nificant (OR = 2.05, 95% CI 1.70 to 2.48, P < 0.00001) (Analysis
1.6). In the comparison of bortezomib versus no bortezomib with
the same background therapy in each arm, OR = 1.51 (95% CI
1.13 to 2.00, P = 0.0048), and for the comparison of bortezomib
versus no bortezomib with different background therapy in each
arm or compared to other agent(s), OR = 2.60 (95% CI 2.01 to
3.35, P < 0.00001). Minor heterogeneity was observed in the stud-
ies of bortezomib versus no bortezomib with the same background
therapy (I2 = 12%), and substantial heterogeneity was observed
in the studies of bortezomib versus no bortezomib with different
background therapy or versus other agent(s) (I2 = 86%), resulting
in substantial heterogeneity across both groups (I2 = 81%). The
test for subgroup differences was significantly different (P = 0.01).
The risk of thrombocytopenia, however, was greater with borte-
zomib in both groups.
Neutropenia
Eight of the 12 trials reported on the frequency of grade three or
four neutropenia. There were 343 cases (18.1%) in 1897 patients
in the bortezomib group and 279 cases (14.8%) in 1894 patients
in the control group. The increased risk of neutropenia in patients
treated with bortezomib was statistically significant (OR = 1.33,
95%CI 1.10 to 1.60, P = 0.003) (Analysis 1.7). In the comparison
of bortezomib versus no bortezomib with the same background
therapy in each arm, OR = 0.95 (95% CI 0.73 to 1.24, P = 0.73)
and for the comparison of bortezomib versus no bortezomib with
different background therapy in each arm or compared to other
agent(s), OR = 1.85 (95% CI 1.41 to 2.41, P < 0.00001). Minor
heterogeneity was observed in the studies of bortezomib versus no
bortezomib with the same background therapy (I2 = 23%), and
substantial heterogeneity observed in the studies of bortezomib
versus no bortezomib with different background therapy or versus
other agent(s) (I2 = 87%), resulting in substantial heterogeneity
across both groups (I2 = 82%). The test for subgroup differences
was significantly different (P = 0.00). The risk of neutropenia was
not significantly different in the studies of bortezomib versus no
bortezomib with the same background therapy, whereas it was sig-
nificantly different in the other comparison group of bortezomib
versus no bortezomib with different background therapy or versus
other agent(s).
Anaemia
Six of the 12 trials reported on the frequency of grade three or
four anaemia. There were 173 cases (10.2%) in 1703 patients in
the bortezomib group and 208 cases (12.2%) in 1701 patients
in the control group. In the comparison of bortezomib versus no
bortezomib with the same background therapy in each arm, OR
= 0.67 (95% CI 0.48 to 0.94, P = 0.02) and for the comparison
of bortezomib versus no bortezomib with different background
therapy in each arm or compared to other agent(s), OR = 0.92
(95% CI 0.69 to 1.21, P = 0.54). The differential risk of anaemia
between the twogroupswas close to reaching statistical significance
between the two groups (OR = 0.80, 95% CI 0.65 to 1.00, P
= 0.05) (Analysis 1.8). Substantial heterogeneity was observed in
the studies of bortezomib versus no bortezomib with the same
background therapy (I2 =70%), andminor heterogeneity observed
in the studies of bortezomib versus no bortezomib with different
background therapy or versus other agent(s) (I2 = 26%), resulting
inmoderate heterogeneity across both groups (I2 = 47%). The test
for subgroup differences was not significantly different (P = 0.16).
Gastro-intestinal adverse events (GI AEs)
Eight of the 12 trials included in the meta-analysis reported GI
AEs. We were unable, however, to extract data on individual GI
AEs from each trial, and the data therefore include counts of all
GI AEs, except where indicated.
Nausea/Vomiting
There were 99 cases (5.2%) in 1894 patients in the bortezomib
group and 44 cases (2.3%) in 1894 patients in the control group.
The increased risk of nausea/vomiting in patients treated with
bortezomib was statistically significant (OR = 2.37, 95% CI 1.64
to 3.42, P < 0.00001) (Analysis 1.9). In the comparison of borte-
zomib versus no bortezomib with the same background therapy
in each arm, OR = 4.55 (95% CI 1.99 to 10.42, P = 0.00033)
and for the comparison of bortezomib versus no bortezomib with
different background therapy in each arm or compared to other
agent(s), OR = 1.93 (95% CI 1.28 to 2.93, P = 0.0018). No het-
erogeneity was observed in the studies of bortezomib versus no
bortezomib with the same background therapy (I2 = 0%), and
moderate heterogeneity observed in the other comparison group
(I2 = 37%), resulting in minor heterogeneity across both groups (I
2 = 27%). The test for subgroup differences was not significantly
different (P = 0.07).
Diarrhoea
There were 116 cases (6.1%) in 1894 patients in the bortezomib
group and 50 cases (2.6%) in 1894 patients in the control group.
The increased risk of diarrhoea in patients treatedwith bortezomib
was statistically significant (OR = 2.44, 95% CI 1.74 to 3.43, P <
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0.00001) (Analysis 1.10). In the comparison of bortezomib versus
no bortezomib with the same background therapy in each arm,
OR = 6.24 (95% CI 2.79 to 13.98, P < 0.00001) and for the com-
parison of bortezomib versus no bortezomib with different back-
ground therapy in each arm or compared to other agent(s), OR =
1.80 (95% CI 1.22 to 2.65, P = 0.0031). Minor heterogeneity was
observed in the studies of bortezomib versus no bortezomib with
the same background therapy (I2 = 10%), and moderate hetero-
geneity observed in the other comparison group (I2 = 57%), re-
sulting in moderate heterogeneity across both groups (I2 = 57%).
The test for subgroup differences was significantly different (P =
0.01), however risk of diarrhoea was greater with bortezomib for
both groups.
Constipation
There were 93 cases (4.9%) in 1894 patients in the bortezomib
group and 60 cases (3.2%) in 1894 patients in the control group.
The increased risk of constipation in patients treated with borte-
zomib was statistically significant (OR = 1.59, 95% CI 1.14 to
2.22, P = 0.0064) (Analysis 1.11). In the comparison of borte-
zomib versus no bortezomib with the same background therapy in
each arm, OR= 1.88 (95%CI 1.04 to 3.41, P = 0.037) and for the
comparison of bortezomib versus no bortezomib with different
background therapy in each arm, or compared to other agent(s),
OR = 1.47 (95% CI 0.98 to 2.20, P = 0.063). No heterogeneity
was observed in either the studies of bortezomib versus no borte-
zomib with the same background therapy or in the other compar-
ison group (I2 = 0%). The test for subgroup differences was not
statistically significant (P = 0.50).
Peripheral neuropathy
Ten of the 12 trials reported on the frequency of grade three or four
peripheral neuropathy. There were 319 cases (13.75%) in 2320
patients in the bortezomib group and 101 cases (4.4%) in 2316
patients in the control group. The increased risk of peripheral
neuropathy in patients treated with bortezomib was statistically
significant (OR = 3.71, 95% CI 2.92 to 4.70, P = P < 0.00001)
(Analysis 1.12). In the comparison of bortezomib versus no borte-
zomib with the same background therapy in each arm, OR = 5.10
(95% CI 3.37 to 7.72, P < 0.00001), and for the comparison
of bortezomib versus no bortezomib with different background
therapy in each arm or compared to other agent(s), OR = 3.09
(95% CI 2.30 to 4.14, P < 0.00001). Moderate heterogeneity was
observed in both the studies of bortezomib versus no bortezomib
with the same background therapy (I2 = 57%), and in the other
comparison group (I2 = 30%), resulting inmoderate heterogeneity
across both groups (I2 = 40%). The test for subgroup differences
was approaching statistical significance (P = 0.05), however, risk of
peripheral neuropathy was significantly greater with bortezomib
in both groups.
Infections (all)
Nine of the 12 trials reported on the frequency of grade three or
four infections. There were 377 cases (17.7%) in 2133 patients in
the bortezomib group and 272 cases (12.75%) in 2133 patients
in the control group. The increased risk of infection in patients
treated with bortezomib was statistically significant (OR = 1.51,
95% CI 1.27 to 1.79, P < 0.00001) (Analysis 1.13). In the com-
parison of bortezomib versus no bortezomib with the same back-
ground therapy in each arm, OR = 1.37 (95% CI 0.97 to 1.93, P
= 0.071) and for the comparison of bortezomib versus no borte-
zomibwith different background therapy in each armor compared
to other agent(s), OR = 1.55 (95% CI 1.27 to 1.90, P < 0.00001).
Minor heterogeneity was observed in the studies of bortezomib
versus no bortezomib with the same background therapy (I2 =
22%) and substantial heterogeneity in the studies of bortezomib
versus no bortezomib with different background therapy or versus
other agent(s) (I2 = 86%), resulting in substantial heterogeneity
across both groups (I2 = 76%). The test for subgroup differences
was not statistically significant (P = 0.54).
Herpes zoster infection
Grade three or four herpes zoster infections were reported in only
four of 12 trials included in the meta-analysis (two trials in each
group). There were 22 cases (2.5%) in 868 patients in the borte-
zomib group and 12 cases (1.4%) in 865 patients in the control
group. The increased risk of herpes zoster infection in patients
treated with bortezomib was not statistically significant (OR =
1.83, 95%CI 0.91 to 3.67, P = 0.091) (Analysis 1.14). In the com-
parison of bortezomib versus no bortezomib with the same back-
ground therapy in each arm,OR = 1.93 (95%CI 0.74 to 5.03, P =
0.79) and for the comparison of bortezomib versus no bortezomib
with different background therapy in each arm or compared to
other agent(s), OR = 1.71 (95% CI 0.62 to 4.74, P = 0.30). No
heterogeneity was observed in the studies of bortezomib versus no
bortezomib with the same background therapy (I2 = 0%), while
very minor heterogeneity was present in the other comparison
group (I2 = 2%), resulting in no heterogeneity across both groups
(I2 = 0%). The test for subgroup differences was not statistically
significant (P = 0.87). It should be noted that an increased risk
of herpes zoster infection associated with bortezomib treatment
has been reported. In the APEX Study, a subset analysis found
that bortezomib was associated with a significantly higher inci-
dence of herpes zoster compared with dexamethasone treatment
(13% versus 5%, P = 0.0002), with most herpes zoster infections
classified as either grade one or two infections, whereas incidences
of grade three or four events and infections that were considered
SAEs, were similar between treatment arms.
Cardiac disorders
Grade three and four cardiac disorders were reported in only five of
12 trials included in themeta-analysis. There were 70 cases (6.4%)
28Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in 1093 patients in the bortezomib group and 42 cases (3.8%)
in 1098 patients in the control group. There was no statistically
significant increased risk of cardiac disorders in patients treated
with bortezomib compared to the control group in the studies
of bortezomib versus no bortezomib with the same background
therapy comprising two trials (OR = 1.17, 95% CI 0.39 to 3.52,
P = 0.78). A significantly elevated risk, however, was detected in
the studies of bortezomib versus no bortezomib with different
background therapy or versus other agent(s) that comprised three
trials (OR=1.84, 95%CI 1.21 to 2.81, P = 0.006) (Analysis 1.15).
No heterogeneity was observed in either or across both groups (I
2 = 0%). The test for subgroup differences was not statistically
significant (P = 0.45).
Fatigue
Fatigue was reported in only five of 12 trials included in the meta-
analysis. There were 84 cases (5.7%) in 1464 patients in the borte-
zomib group and 44 cases (3.0%) in 1462 patients in the control
group. The increased risk of fatigue in patients treated with borte-
zomib compared to the control group was statistically significant
(OR = 1.96, 95% CI 1.35 to 2.84, P = 0.0004) (Analysis 1.16).
In the comparison of bortezomib versus no bortezomib with the
same background therapy in each arm, OR = 3.30 (95% CI 1.66
to 6.58, P = 0.00069) and for the comparison of bortezomib ver-
sus no bortezomib with different background therapy in each arm
or compared to other agent(s), OR = 1.52 (95% CI 0.97 to 2.38,
P = 0.070). No heterogeneity was observed in the studies of borte-
zomib versus no bortezomib with the same background therapy
(I2 = 0%), with moderate heterogeneity in the other comparison
group (I2 = 39%), resulting in moderate heterogeneity across both
groups (44%). The test for subgroup differences was borderline
statistically significant (P = 0.06).
Health-related quality of life (HRQoL)
Only four trials included HRQoL outcomes (APEX Study;
NMSG 15/05 Study; NMSG 17/07 Study; VISTA Study,). Each
trial used the same validated quality of life instrument (European
Organization for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire (QLQ-C30), whereas the time
points of administration of the questionnaire varied between the
four trials. Detailed quality of life analyses were performed in
the VISTA Study and in the APEX Study. The APEX study also
measured neurotoxicity using the Functional Assessment of Can-
cer Therapy/GynecologicOncologyGroup-Neurotoxicity (NTX)
side-effects questionnaire. As the number of trials with quality of
life outcomes data was relatively small (four of 12 trials) and the
data reported for some trials insufficient, we could not perform
meta-analysis on this outcome.
In summary, data from the APEX Study (bortezomib versus no
bortezomib with different background therapy or versus other
agent(s)) indicated that patients treated with bortezomib had sig-
nificantly bettermeanGlobalHealth Status when compared to pa-
tients receiving dexamethasone. Patients treated with bortezomib
also had significantly better physical health, role, cognitive, and
emotional functioning scores, lower dyspnoea and sleep symp-
tom scores. Better NTX questionnaire scores were observed on
the bortezomib arm when compared to the dexamethasone arm,
despite a significantly greater incidence of greater than or equal
to grade three peripheral neuropathy in those who received borte-
zomib. This observation could be due to the range of measures
assessed by the NTX scale that are not related to peripheral neu-
ropathy.
Limited quality of life data was reported in the NMSG 15/05
Study comparing bortezomib consolidation with no consolidation
therapy post transplant setting (bortezomib versus no bortezomib
with the same background therapy). After eight weeks of study
treatment, a statistically significant increase in fatigue and nausea
or vomiting was observed in the bortezomib group (P < 0.01),
with fatigue reported as reaching the cut-off for clinical relevance.
However, there were no significant differences in HRQoL scores
between the bortezomib arm and the control arm. In the NMSG
17/07 Study of bortezomib and dexamethasone versus thalido-
mide and dexamethasone in melphalan-refractory patients (borte-
zomib versus no bortezomib with different background therapy
or versus other agent(s)), no difference was seen for any of the
quality of life domains measured, with the exception of fatigue
which was observed to be worse in the bortezomib arm (P = 0.04).
A significantly higher score for sleep disturbance was observed in
the bortezomib arm at 12 weeks of treatment (P < 0.01).
Finally, in the VISTA Study of bortezomib, melphalan and pred-
nisone (VMP) versus melphalan and prednisone (MP) in trans-
plant ineligible myeloma (bortezomib versus no bortezomib with
the same background therapy), patients experienced clinically
meaningful lower quality of life domain scores after four cycles of
treatment with VMP. Improvements on the VMP arm compared
to the baseline and to the MP arm were observed from cycle five,
while mean scores generally improved by the end-of-treatment as-
sessment versus baseline in both arms. Improved HRQoL was ob-
served in the analyses of patients receiving a lower dose intensity
of bortezomib, while multivariate analysis suggested clinically and
statistically significant improvements in domains of global health
status. In addition, it was found that lower scores for pain, ap-
petite loss and diarrhoea may occur in patients who respond to
treatment and in particular those patients who achieve CR.
Comparison 3: Dose and Schedule Studies
Four trials assessed bortezomib dose comparisons, methods
of administrations and treatment schedules (CREST Study;
GEM2010MAS65 Study; IFM 2007-02 Study; MMY-3021
Study), and were assessed qualitatively only.
The CREST Study was the first published randomised study of
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bortezomib to evaluate the safety and efficacy of twodoses of borte-
zomib in 54 patients who had relapsed after, or were refractory
to frontline therapy. Patients received intravenous bortezomib at
doses of 1.0 mg/m2 or 1.3 mg/m2 twice weekly for two weeks ev-
ery three weeks for up to eight cycles. Dexamethasone was permit-
ted in patients with either progressive or stable disease after two
or four cycles, respectively. The primary outcomes were response
rates, and secondary outcomes were response rate to bortezomib
in combination with dexamethasone, TTP on bortezomib alone
and in combination with dexamethasone.
The GEM2010MAS65 Study was a randomised open-label phase
III trial that compared VMP to Lenalidomide plus dexamethasone
(Rd) in a sequential versus an alternating scheme in 242 elderly
patients > 65 years with newly diagnosed myeloma. Patients re-
ceived either a sequential scheme of nine cycles of VMP followed
by nine cycles of Rd or the same regimens in an alternating ap-
proach (one cycle of VMP alternating with one Rd (half of the
patients started by VMP and half by Rd) for up to 18 cycles. The
primary outcomeswere TTP and toxicity and secondary outcomes
were response, genomics analysis, duration of response, PFS, time
to next therapy and OS. This study has only been published by
conference abstract to date.
The IFM 2007-02 Study was a randomised open-label phase III
trial and compared bortezomib-dexamethasone (VD) as induc-
tion therapy versus a combination of reduced doses of bortezomib
and thalidomide plus dexamethasone (vtD) in 199 patients with
newly diagnosed myeloma. The primary outcome was post-induc-
tion complete response rate (CRR) and secondary outcomes were
CR plus very good partial response (VGPR) rates after cycle two,
after induction and after autologous stem cell transplant, overall
response rates (ORR) (≥ partial response (PR)) after cycle two,
after induction and after autologous stem cell transplant., safety
and toxicity.
The MMY-3021 Study was a randomised open-label phase III
non-inferiority trial of subcutaneous versus intravenous adminis-
tration of bortezomib in 222 patients with measurable progressive
disease who had received one to three prior therapies. The primary
outcome was ORR after four cycles and secondary outcomes were
CR, nCR and VGPR after four cycles, ORR after eight cycles,
time to response, duration of response, TTP, PFS, one-year OS,
safety and tolerability, pharmacokinetics and pharmacodynamics.
The initial trial report demonstrated non-inferior efficacy with
subcutaneous versus intravenous bortezomib for ORR after four
cycles of single-agent bortezomib.
Overall Survival (OS)
In the CREST Study, one- and five-year survival rates were 82%
and 32%, respectively, in the 1.0mg/m2 group and 81%and 45%,
respectively, in the 1.3 mg/m2 group. In the GEM2010MAS65
Study, after amedian follow-up of 27months,OSwas not reached.
Patients who achieved a complete response had significantly longer
OS (and PFS) when compared with patients who did not achieve
CR in both arms and patients younger than 75 years demonstrated
significantly improved survival when compared to patients ≥ 75
years, however there was no significant difference between the
arms. In the IFM 2007-02 Study, there was no difference regard-
ingOS between the two arms (VDversus vtD). In theMMY-3021
Study, which tested for non-inferiority, one-year OS was not sig-
nificantly different between the treatment arms of subcutaneous
versus intravenous bortezomib (72.6%, 95% CI 63.1 to 80.0 ver-
sus 76.7%, 95% CI 64.1 to 85.4, P = 0.504).
Progression-Free Survival (PFS)
In the CREST Study, median TTP was 7.0 months and 11.0
months in the 1.0 mg/m2 and 1.3 mg/m2 groups respectively.
In the GEM2010MAS65 Study, after a median follow-up of 27
months, PFS was not significantly different between the arms (30
months in both arms). In the IFM 2007-02 Study, there was no
difference in median PFS between the two arms (30 months in
the VD arm versus 26 months in the vtD arm, P = 0.22). In the
MMY-3021 Study, there were no significant differences in TTP
between the treatment arms of subcutaneous versus intravenous
bortezomib (median 10.4 months, 95% CI 8.5 to 11.7 versus 9.4
months, 95% CI 7.6 to 10.6; P = 0·387).
Adverse Events (AEs)
Themost commonly reported adverse events (AEs) in the CREST
Study were fatigue (70%), nausea (54%), diarrhoea (44%),
pyrexia (41%), constipation (37%), peripheral neuropathy (41%),
arthralgia (35%), insomnia (35%), headache (31%), limb pain
(31%), thrombocytopenia (30%) and upper respiratory tract in-
fection (30%). In the GEM2010MAS65 Study, no significant
differences were observed between the sequential and alternating
arms in the frequency of grade three or four neutropenia (19%
and 22%), thrombocytopenia (21% and 20%), and 3% and 6%
of patients in the sequential and alternating arms had grade three
or four infections. No differences were observed in the incidence
of peripheral neuropathy in the sequential and alternating arms
(4% and 3%, respectively), nor in the rate of grade three or four
thrombotic events (1% and 2%). In the IFM 2007-02 Study, the
proportion of patients with at least one AE of grade three or higher
was not different between the two groups. Grade three or four
haematological or non-haematological toxicities, with the excep-
tion of peripheral neuropathy were rare, with no significant differ-
ences between the arms. The incidence of peripheral neuropathy
was 70% in the VD arm versus 53% in the vtD arm (P = 0.01).
Grade two peripheral neuropathy was much higher in the VD arm
than vtD arm and grade three peripheral neuropathy was seen in
11% of patients with VD compared to 3% with vtD (P = 0.03),
with four patients discontinuing treatment because of peripheral
neuropathy in the VD arm versus none in the vtD arm.
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In the MMY-3021 Study, grade three or worse AEs were reported
in 84 (57%) patients in the subcutaneous group versus 52 (70%)
in the intravenous group. The most common AEs were thrombo-
cytopenia (19 (13%) versus 14 [(19%)), neutropenia (26 (18%)
versus 13 (18%)), and anaemia (18 (12%) versus six (8%)). Pe-
ripheral neuropathy of any grade (56 (38%) versus 39 (53%); P
= 0·044), grade two or worse (35 (24%) versus 30 (41%); P =
0·012), and grade three or worse (nine (6%) versus 12 (16%); P
= 0·026) was significantly less common with subcutaneous than
with intravenous administration.
Subgroup analysis - disease setting
We considered three subgroups for myeloma disease setting: trans-
plant eligible, transplant ineligible and relapsed/refractory disease
and included 11 trials in this subgroup analysis (we did not include
the All India Institute Study as the disease setting was unclear).
We performed subgroup analyses for OS, PFS, CRR and ORR
(Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4).
For OS, a statistically significant benefit with bortezomib treat-
ment was observed in all groups, with the smallest benefit observed
in the transplant eligible group. Considering this group alone, the
benefit was not statistically significant with a Peto odds ratio (OR)
of 0.86 (95% CI 0.73 to 1.02) (Analysis 2.1). For PFS, the ob-
served benefit for bortezomib was lower in the transplant eligible
group than the other two groups but still statistically significant
(Analysis 2.2). There was evidence of heterogeneity between sub-
groups for PFS (P = 0.002, I² = 84.5%).
Subgroup analysis - therapy setting
We considered three subgroups for myeloma therapy setting: in-
duction, consolidation and maintenance and included six trials
in the subgroup analysis for therapy setting. We also performed
subgroup analyses for OS, PFS, CRR and ORR (Analysis 3.1;
Analysis 3.2; Analysis 3.3; Analysis 3.4).
A statistically significant benefit for bortezomib was observed in
all outcomes and subgroups except for OS following consolida-
tion therapy. Heterogeneity tests between subgroups were non-
significant for all outcomes.
D I S C U S S I O N
Summary of main results
The goal of this systematic review and meta-analysis was to syn-
thesise all available data on the effects of bortezomib treatment
for multiple myeloma.We identified 16 relevant randomised con-
trolled trials (RCTs) involving 5626 patients and 12 trials were
included in the meta-analyses. Among these 12 trials, six trials in-
volving 2247 patients evaluated bortezomib versus no bortezomib
with the same background therapy in each arm, while another
six trials involving 2663 patients evaluated bortezomib versus no
bortezomib with either different background therapy in each arm
or compared to other agents. An additional four trials involving
716 patients assessed bortezomib dose comparisons, methods of
administrations and treatment schedules. The trials in this group
were too dissimilar for meta-analysis and were therefore assessed
qualitatively. We identified four trials in the meta-analysis that
measured time to progression (TTP) as an outcome and were able
to extract and analyse progression-free survival (PFS) data for three
of the studies, while in the case of the APEX Study, we included
TTP data as PFS data were not available. We therefore did not
analyse TTP separately.
From this systematic review and meta-analysis we can summarise
the following.
• A clear benefit in overall and progression-free survival (PFS)
in favour of bortezomib is observed in the pooled analysis of
trials and for each pf the comparison groups analysed.
• Patients treated with bortezomib also had overall (ORR)
and complete response rates (CRR) that were significantly higher
than in controls in the pooled analysis and also for each of the
comparison groups analysed.
• Patients treated with bortezomib had significantly greater
risk of thrombocytopenia, neutropenia, gastro-intestinal
toxicities, peripheral neuropathy, infection and fatigue. A greater
risk of cardiac disorders was observed only in the studies of
bortezomib versus no bortezomib with different background
therapy in each arm or versus other agents and there was no
evidence of increased risk of treatment-related death (TRD) in
either of the groups analysed.
• From the qualitative analysis of four trials that evaluated
dose and schedule studies, an improved benefit was observed
with a dose of 1.3 mg/m2 compared to 1.0 mg/m2 in the
CREST Study; and this dose has been the approved starting dose
level for bortezomib. The MMY-3021 Study also showed that
subcutaneous administration of bortezomib is non-inferior to
intravenous administration and also a significantly lower
incidence of peripheral neuropathy was observed with
subcutaneous administration.
• Health-related quality of life (HRQoL) was only examined
in four trials. Improved Global Health Status was observed with
bortezomib in the APEX Study, while no difference in quality of
life measures were observed between arms in the NMSG 15/05
Study and NMSG 17/07 Study, with some symptoms e.g.
fatigue, sleep disturbance significantly worse in the bortezomib
group. In the VISTA Study, quality of life was worse in the
bortezomib group after four cycles, but improved after five cycles
of treatment and also at the end-of-treatment assessment.
• Subgroup analyses by disease setting revealed improvements
in all outcomes. Moderate to substantial heterogeneity was
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observed between the subgroups, with the smallest benefit seen
in transplant eligible patients. In the case of overall survival
(OS), the benefit for bortezomib was not statistically significant.
• In the subgroup analyses by therapy setting, a statistically
significant benefit for bortezomib was observed in all outcomes
and subgroups, except for that of OS following consolidation
therapy. However, the heterogeneity test comparing the
treatment effect in this subgroup with the other groups was not
significant. As such, there is little justification for treating this
subgroup as different from the others, and therefore we are
unable to conclude that there was no OS benefit for bortezomib
in this specific setting.
Overall completeness and applicability of
evidence
Sixteen published RCTs are included in this review of bortezomib
treatment formultiplemyeloma.Of the included studies, sixRCTs
assessed the efficacy and safety of bortezomib versus no borte-
zomib, in the setting of identical background therapy, whereas
another six RCTs had different background therapy in each arm.
Both of these groups of trials (a total of 12 studies) were included
in the meta-analysis. Another four RCTs assessed different borte-
zomib dose, administration and treatment schedules, but could
not be included in the meta-analysis. A majority of included stud-
ies (14 of 16) were published as full-text articles and only two
studies in abstract form. Of the 12 studies included in the meta-
analysis, eight studies provided data on OS, nine studies provided
data on PFS and 12 studies provided data on response rates. All
studies reported adverse effect (AE) data, although not for all of
the individual AEs reported in this review. Only five of 12 trials
reported the incidence of TRD and only four trials included anal-
yses of health-related quality of Life (HRQoL).
We therefore conclude that the completeness and applicability of
the evidence in this review to be generally moderate to high for
the outcomes relevant to this review.
We are aware of 15 ongoing or unpublished studies
(see Characteristics of studies awaiting classification and
Characteristics of ongoing studies) from a review of clinical tri-
als registries that may be included in a future update of this re-
view. At least three trials were identified as completed in 2013
through searches of clinical trials registries (Consolidation (61-75
years) Study; Consolidation (less than 60 years) Study; King Fasail
Hospital Study), however these trials are not yet published and no
further data have been provided by the authors. An assessment of
the published articles, however, will be required in order to deter-
mine their eligibility for inclusion.
Quality of the evidence
The risk of bias in all 16 studies included in this review has been
analysed in detail. Two included trials were published in abstract
form (All India Institute Study; GEM2010MAS65 Study). We
were therefore unable to fully assess the potential risk of bias in
these studies. All included studies had an open-label design, while
seven studies had unclear allocation concealment that could sug-
gest selection and performance biases. Six studies had unclear
blinding of outcome assessment, which could lead to detection
bias. Attrition and reporting bias were considered to be at low risk
for themajority of studies. One aspect was considered to be at high
risk of bias in one study (All India Institute Study, where reporting
bias was felt to be a potential issue. We judged the overall risk
of bias of included trials as generally low and therefore could be
considered to be of adequate methodological quality. Collectively,
the quality of evidence for the main comparisons was high for OS
(mortality) but low for PFS, primarily due to trial heterogeneity.
Significant heterogeneity was observed in the analysis of PFS, par-
ticularly in the comparison group of bortezomib versus no borte-
zomib with different background therapy or other agents. This
heterogeneity may have arisen as a result of this comparison being
confounded by the presence of other treatments. Also, differences
in the methods used for response assessment across trials may have
also contributed to variability in the data; trials either employed
the IMWG (International Myeloma Working Group guidelines)
or EBMT (European Group for Blood and Marrow Transplant)
response criteria. In addition, only some trials conducted central
or independent review of response assessments, which may also
have been a contributory factor. Quality of evidence for TRD was
moderate due to low number of events and wide confidence inter-
vals. Quality of evidence for HRQoL could not be evaluated due
to few trials evaluating this outcome.
Potential biases in the review process
To prevent potential biases in the review process, we considered
only RCTs. We attempted to avoid biases by conducting all review
processes (trial searching, data extraction and analysis) in dupli-
cate, by two review authors working independently. Any disagree-
ments were discussed in order to reach consensus. Overall, we are
confident that all relevant studies were identified and included and
all review processes were followed according to Cochrane recom-
mendations.
We did not identify any evidence of publication bias, however a
number of trials were identified as ongoing and three trials were
reported as complete in 2013 but not yet published, therefore we
could not include data from these trials in this review.
Agreements and disagreements with other
studies or reviews
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To our knowledge this is the first comprehensive systematic review
and meta-analysis of bortezomib treatment for multiple myeloma
across all disease and therapy settings. We searched for published
reviews and/or health technology reports with systematic searches
of databases and identified the following publications.
We identified three systematic reviews andmeta-analyses that have
been conducted to evaluate the efficacy of bortezomib for the
treatment of myeloma in specific disease or therapy settings.
Nooka 2013 performed a meta-analysis of RCTs of bortezomib-
containing induction regimens (BICR) in transplant eligible
myeloma patients, and identified four eligible trials, all of which
are included in our review. In their review, the impact of BCIR ver-
sus non-bortezomib-containing induction regimens (NBCIR) on
responses rates, PFS and OS and on regimen-related grade three
toxicities was analysed. The pooled hazard ratios (HR) for three-
year PFS and OS were 0.71 (95% confidence interval (CI), 0.60
to 0.83, P < 0.00001) and 0.79 (95%CI, 0.66 to 0.96, P = 0.014),
respectively in favour of BCIR. Response rates were statistically
significantly in favour of BICR. These findings would also be in
agreement with our subgroup analyses of induction therapy trials
(Analysis 3.1 to Analysis 3.4).
Sonneveld 2013 also performed a meta-analysis of clinical tri-
als involving induction regimens containing bortezomib versus
no bortezomib, and included the same four trials in the review
by Nooka 2013, also included in our review. They analysed pa-
tient-level data from three of the trials and study-level data from
a fourth trial due to legal restrictions on data access. Complete
response rates were significantly higher post-transplant following
bortezomib-based versus non bortezomib-based induction ther-
apy (38% versus 24%; OR = 2.05 (95% CI, 1.64 to 2.56, P =
0.001) and this benefit remained when the fourth trial data was
included (pooled odds ratio (OR) = 1.96). Median PFS was 35.9
months versus 28.6 months with bortezomib-based versus non
bortezomib-based induction, respectively (HR = 0.75, P = 0.001)
and three-year OS (HR = 0.81, P = 0.0402).
Finally, Zeng 2013 performed a systematic review and meta-anal-
ysis of clinical trials of bortezomib for patients with previously
untreated myeloma and included five trials, all of which are in-
cluded in our review. They included three trials that compared
bortezomib with no bortezomib, and two that compared borte-
zomib with other treatments (vincristine/Adriamycin-based che-
motherapy) in their analysis. Compared with no bortezomib or
vincristine-based chemotherapy, the bortezomib-based regimen
significantly improved OS: HR = 0.71 (95 % CI 0.55 to 0.93)
and HR = 0.77 (95 % CI 0.60 to 0.99), respectively. However,
they found when compared with the vincristine plus Adriamycin-
based regimen, the OS was similar (HR = 0.87, 95% CI 0.57 to
1.33). Other efficacy outcomes such as TTP, PFS, and response
rates were also improved in patients receiving the bortezomib-
based regimen.
All three reviews reported significantly higher rates of adverse
events, especially peripheral neuropathy with bortezomib-based
regimens. The results of these three systematic reviews and meta-
analysis are therefore in agreement with the findings in our review.
A Health Technology Assessment (HTA) conducted in the UK
summarised RCT evidence for clinical effectiveness as a narrative
summary and cost-effectiveness analysis of bortezomib or thalido-
mide in combination with an alkylating agent and a corticosteroid
for first-line treatment (Picot 2011). This review included only
one trial of bortezomib treatment (VISTA Study), and found that
VMP (bortezomib, melphalan, and prednisone) could be consid-
eredmore clinically effective thanMP (melphalan and prednisone
alone) for the first-line treatment of myeloma in patients ineligible
for high-dose therapy and stem cell transplant.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review and meta-analysis focused on clinically rel-
evant outcomes, such as response rates, survival and adverse events.
Our review found that treatment of myeloma with bortezomib
leads to statistically significant improvements in response rates
and in the duration of progression-free and overall survival across
myeloma disease and therapy settings. Bortezomib, however, also
induces significant toxicity that may be dose-limiting. As a result,
recommended dose modification schedules as well as appropriate
evidence-based prophylaxis and supportive care regimens should
be used for the duration of therapy. Premature discontinuation of
therapy due to toxicity such as peripheral neuropathy will prevent
such patients benefiting from this effective agent.
We conclude that bortezomib should be considered to be a stan-
dard therapy for multiple myeloma.
There is insufficient evidence, however, to draw any conclusions
regarding the optimal combination therapy involving bortezomib.
Implications for research
While substantial clinical evidence has accumulated to support the
use of bortezomib as a treatment for multiple myeloma, clinical
trials of newer proteasome inhibitors are also needed. A number
of novel proteasome inhibitor drugs are in clinical development,
the most advanced of which is carfilzomib. A global assessment
of novel agents should encompass not only survival and response
outcomes but also adverse effects and patient quality of life. In ad-
dition, given the increasing cost of anti-cancer therapies on health
budgets, a formal evaluationof the cost-effectiveness of these newer
proteasome inhibitor drugs should be routinely included in cost-
benefit analyses. In summary, further research should encompass
the following.
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• The optimal proteasome inhibitor to be included in
combination regimens for the treatment of myeloma in each
disease and therapy setting.
• Further evaluation of clinical and biologic prognostic
markers, for example fluorescence in situ hybridisation (FISH)
cytogenetic profiles and their influence on response to treatment
with proteasome inhibitors.
• Further evaluation on the dose and scheduling of
proteasome inhibitors in order to improve the toxicity profile of
this class of agent and for optimal health-related quality of life.
• Mechanisms of resistance to proteasome inhibitors should
be identified and strategies to overcome resistance developed.
• Predictors of response to proteasome inhibitor treatment
should be identified, such that treatment can be tailored to
individual myeloma patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
All India Institute Study
Methods • Design: Randomised open-label trial conducted at the All India Institute of
Medical Science, Delhi, India from Feb 2011 to Sep 2012.
• Sample size: N = 43 patients. Experimental arm (BD) = 22 patients. Control arm
(CTD) = 21 patients.
Participants • Patient Population:Multiple myeloma with light-chain induced acute renal
failure.
• Inclusion/Exclusion Criteria: Not reported.
• Baseline Characteristics: Not reported.
Interventions • Experimental Arm (BD): IV bortezomib 1.3 mg/m2, oral dexamethasone 40 mg
both weekly, q 4 weekly.
• Control Arm (CTD): Oral cyclophosphamide 100 mg/m2 for 7 days, oral
thalidomide 100 mg daily and oral dexamethasone 40 mg/week, q 4 weekly.
• Additional Treatments: Not reported.
Outcomes • Renal response and myeloma response according to IMWG Criteria.
Notes • Sponsor/Funding: Not reported.
• Type of Publication (Full text or abstract only): Abstract only.
• Linked to other reports: None.
• IMWG = International Myeloma Working Group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study design described as ’randomised’ in
title however randomisation methods not
reported
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective outcomes measured (e.g. re-
sponse rate and progression according to
IMWG guidelines, number of patients
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All India Institute Study (Continued)
alive). Independent blinded outcomes as-
sessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patient status reported at median follow-
up of 7.5 months.
Selective reporting (reporting bias) High risk Key eligibility criteria not reported. Base-
line characteristics per arm not reported.
Selected adverse events reported only
Other bias Unclear risk Not reported.
APEX Study
Methods • Design: Randomised, open-label, phase III trial conducted at 93 centres in the
US, Canada, Europe and Israel from Jun 2002 to Oct 2003.
• Sample size: N = 669 patients. Experimental arm (bortezomib) = 333 patients.
Control arm (high-dose dexamethasone) = 336 patients.
• Cross-over: Patients on the high-dose dexamethasone were permitted to cross-
over to the bortezomib arm at disease progression.
Participants • Patient Population:Multiple myeloma patients with measurable progressive
disease after 1 to 3 previous treatments.
• Inclusion Criteria: KPS) ≥ 60%; platelets ≥ 50,000/mL3 ; haemoglobin ≥ 7.5g/
dL; ANC ≥750/mL3 ; creatinine clearance 20 mL/min.
• Exclusion Criteria: Disease refractory to high-dose dexamethasone; ≥ grade 2
peripheral neuropathy.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • Experimental arm: IV bortezomib 1.3 mg/m2 on days 1, 4, 8, 11 of cycles 1 to 8
(21-day cycle) and days 1,8, 15, 22 of cycles 9 to 11 (35-day cycle). Maximum
treatment period = 273 days.
• Control arm: Oral dexamethasone 40 mg on days 1 to 4, 9 to 12, 17 to 20 of
cycles 1 to 4 (35-day cycle) and days 1 to 4 of cycles 5 to 9 (28-day cycles). Maximum
treatment period = 280 days.
• Additional Treatments: Platelet and red-cell transfusions, neutrophil growth
factors and epoetin alfa. IV bisphosphonates unless clinically contraindicated.
Outcomes • Primary: Time to disease progression.
• Secondary: Overall survival; 1-year survival; response rate (complete plus partial
response); duration of response; time to first evidence of confirmed response; time to
first infection ≥ grade 3; incidence of ≥ grade 3 infection; time to first skeletal event;
adverse events; health-related quality of life.
Notes • Sponsor/Funding: Millennium Pharmaceuticals.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: Richardson, 2007 (extended follow-up data).
• KPS = Karnofsky Performance Status.
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APEX Study (Continued)
• ANC = Absolute Neutrophil Count.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Unclear risk Not specified. Central randomisation
probably performed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression by the Euro-
pean Group for Blood and Bone Marrow
Transplant (EBMT) criteria, overall sur-
vival). Response data based on central lab-
oratory analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data for the final analyses of the time to
disease progression and the response were
censored. Full details of censoring reported
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk Not reported.
CREST Study
Methods • Design: Exploratory, randomised, open-label, phase II trial conducted at 10
centres in the US from May 2001 to Jan 2002.
• Sample size: N = 54 patients. Arm A (1.0 mg/m2 bortezomib) = 28 patients.
Arm B (1.3 mg/m2 bortezomib) = 26 patients.
• Trial not designed to conduct formal statistical comparisons between groups.
Participants • Patient Population:Multiple myeloma patients with relapsed/refractory disease
who have received front-line therapy only.
• Eligibility Criteria: Age ≥ 18 years; KPS) ≥ 60%; life expectancy > 3 months;
platelets ≥ 30 x 109/L; haemoglobin ≥ 8 g/dL; ANC ≥ 0.5 x 109/L; creatinine
clearance ≥ 30 mL/min; bilirubin ≤ 2 x ULN; AST or ALT ≤ 3 x ULN.
• Baseline Characteristics: Some imbalances noted. More females, patients with
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IgG myeloma and patients with abnormal cytogenetics in 1.3 mg/m2 group. More
patients with platelets < 75 x 109/L at baseline in 1.0 mg/m2 group.
Interventions • Arm A: Bortezomib 1.0 mg/m2 IV days 1, 4, 8, 11 of 21-day cycle up to 8 cycles.
• Arm B: Bortezomib 1.3 mg/m2 IV days 1, 4, 8, 11 of 21-day cycle up to 8 cycles.
• Additional Treatments: Patients with progressive disease after 2 cycles, or stable
disease after 4 cycles were eligible to receive 20 mg oral dexamethasone on the day of,
and day following bortezomib treatment.
Outcomes • Primary: Overall response rate (ORR): sum of complete response (CR), partial
response (PR) and minimal response (MR).
• Secondary: Response rate to bortezomib in combination with dexamethasone;
time to progression on bortezomib alone and in combination with dexamethasone;
overall survival; safety.
Notes • Sponsor/Funding: Millennium Pharmaceuticals.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: Jagannath, 2008 (extended follow-up data).
• KPS = Karnofsky Performance Status.
• ANC = Absolute Neutrophil Count.
• AST = Aspartate aminotransferase.
• ALT = Alanine aminotransferase.
• IgG = Immunoglobulin G.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Randomisation envelopes at each centre se-
lected based on stage of disease and front-
line chemo-therapeutic regimen. Type of
envelope used e.g. opaque and who had
access to the envelopes not adequately re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression by the Euro-
pean Group for Blood and Bone Marrow
Transplant (EBMT) criteria, overall sur-
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vival). Response data assessed by indepen-
dent review committee of 3 myeloma ex-
perts independent of trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patient status at > 5-year median follow-up
reported.
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk Not reported.
GEM05MENOS65 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 66 centres in Spain
from Apr 2006 to Aug 2009.
• Randomisation to one of 3 induction therapy arms (N = 386 patients):
1. Arm A = VTD (bortezomib, thalidomide, dexamethasone) = 127 patients
2. Arm B = TD (thalidomide, dexamethasone) = 130 patients
3. Arm C = VBMCP/VBAD/B (vincristine, BCNU, melphalan, cyclophosphamide,
prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib) = 129
patients
• Post ASCT, randomisation to one of 3 maintenance therapy arms (N = 266
patients):
1. Arm A = TV (thalidomide, bortezomib) = 89 patients
2. Arm B = T (thalidomide only) = 87 patients
3. Arm C = alfa2-IFN (Interferon alpha-2b) = 90 patients
Participants • Patient Population: Patients with newly diagnosed and untreated symptomatic
multiple myeloma.
• Inclusion Criteria: Age ≤ 65 years; PS < 3; Platelets ≥ 50x109/L; Haemoglobin
≥ 8 g/dL; ANC ≥ 1x109/L; serum creatinine ≤ 2 mg/dL.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • Induction Therapy (24 weeks):
1. Arm A: VTD: TD as per Arm B and IV bortezomib 1.3 mg/m2 on D1, 4, 8 and
11 of each cycle.
2. Arm B: TD: Oral thalidomide 200 mg daily (escalating dose first cycle), oral
dexamethasone 40 mg D1-4 and 9-12 for 6 cycles.
3. Arm C: VBMCP/VBAD/B: VBMCP and VBAD chemotherapy plus bortezomib
for 4 cycles alternating VBMCP and VBAD.
• Maintenance Therapy (3 years):
1. Arm A: TV: Oral thalidomide 100 mg per day plus 1 cycle of bortezomib on D1,
4,8 and 11 every 3 months.
2. Arm B: T: Oral thalidomide 100 mg per day.
3. Arm C: alfa2-IFN: Interferon alpha-2b SC 3MU 3 times per week.
• Additional Treatments: LMW heparin/aspirin for thromboprophylaxis for
patients receiving thalidomide, zoledronic acid up to 2 years.
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Outcomes • Primary: Complete response rate after induction and after ASCT.
• Secondary: Progression-free survival, overall survival and safety.
Notes • Sponsor/Funding: PETHEMA Foundation supported by 2 grants from Janssen-
Cilag and Pharmion.
• Type of Publication (Full Text or abstract only): Full text.
• Linked to other reports: Rosinol, 2012 (maintenance data).
• PS = Performance Status.
• ANC = Absolute Neutrophil Count.
• LMW = Low molecular weight.
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Patients were ’centrally randomised’.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate according to the European
Group for Blood and Bone Marrow Trans-
plant (EBMT) criteria, overall survival).
Response data and toxicity monitored by
an external contract research organisation
and centrally reviewed by the principal in-
vestigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk Acceptable rates of withdrawal during in-
duction therapy reported
Selective reporting (reporting bias) Unclear risk Benefits and harms reported, however se-
lected adverse events reported only
Other bias Unclear risk Not reported.
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Methods • Design: Randomised, open-label, phase III trial conducted in Spain.
• Overall sample size: N = 241 patients. Experimental arm (alternating scheme) =
120 patients. Control arm (sequential scheme) = 121 patients.
Participants • Patient Population: Elderly patients with newly diagnosed multiple myeloma.
• Inclusion Criteria: Age > 65 years; ECOG PS ≤2; platelets ≥ 75 x 109/L;
haemoglobin ≥ 8 g/dL; ANC ≥ 1.0 x 109/L; serum bilirubin ≤ 1.5 mg/dL; alkaline
phosphatase, AST, ALT ≤ 2.5 x ULN; serum creatinine ≤ 2.5 mg/dL.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; prior bortezomib or
lenalidomide.
• Baseline Characteristics: Not known.
Interventions • Sequential scheme: 9 cycles of VMP (IV bortezomib 1.3 mg/m2 twice weekly for
1 six-week cycle followed by once weekly for 8 four-weeks cycles, oral melphalan 9 mg/
m2, prednisone 60 mg/m2 once daily on days 1-4 of each cycle) followed by 9 cycles of
Rd (oral lenalidomide 25 mg daily on days 1-21, dexamethasone 40 mg weekly).
• Alternating scheme: One cycle of VMP alternating with one cycle of Rd (half of
patients started VMP and half by Rd) for up to 18 cycles.
Outcomes • Primary: Time to progression; toxicity (safety and tolerability).
• Secondary: Response; genomics analysis; duration of response; progression-free
survival, time to next therapy; overall survival.
Notes • Sponsor/Funding: PETHEMA Foundation.
• Type of Publication (Full text or abstract only): Abstract only.
• Linked to other reports: None.
• ECOG PS = Eastern Coooperative Oncology Group Performance Status.
• ANC = Absolute Neutrophil Count.
• AST = Aspartate aminotransferase.
• ALT = Alanine aminotransferase.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Unclear risk Not known. Central randomisation prob-
ably performed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective endpoints measured (e.g. re-
sponse rate according to the European
Group for Blood and Bone Marrow Trans-
plant (EBMT) criteria, overall survival).
Not known if blinded/independent out-
comes assessment conducted
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear if any patients lost to follow-up,
withdrawn etc (abstract only)
Selective reporting (reporting bias) Unclear risk Not clear (abstract only). Benefits and
harms reported.
Other bias Unclear risk Not reported.
GIMEMA-MM-03-05 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 61 centres in Italy
from May 2006 to Jan 2009.
• Overall sample size: N = 511 patients. Experimental arm (VMPT-VT) = 254
patients. Control arm (VMP) = 257 patients.
Participants • Patient Population: Patients with newly diagnosed transplant ineligible multiple
myeloma.
• Inclusion Criteria: Age ≥ 65 years; not candidates for high-dose therapy plus
stem cell transplantation due to age or co-existing co-morbidities; KPS ≥ 60%.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; renal insufficiency
(creatinine ≥ 25 mg/mL); psychiatric disease; uncontrolled/severe cardiovascular
disease; other malignancy within 5 years.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • Experimental arm (VMPT-VT): Induction therapy with nine 6-weekly cycle of
IV bortezomib 1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, 32 of cycles 1to 4 and on
days 1, 8, 22, 29 of cycles 5-9, oral melphalan 9 mg/m2 on days 1 to 4, oral prednisone
60 mg/m2 on days 1 to 4, oral thalidomide 50 mg/day continuously. Maintenance
therapy with IV bortezomib 1.3 mg/m2 every 14 days and oral thalidomide 50mg/day
for 2 years or until progression.
• Control arm (VMP): Standard induction therapy with nine 6-weekly cycles of
VMP at same doses and no maintenance therapy.
• Post safety analysis of 139 patients, induction changed to nine 5-week cycles and
weekly bortezomib cycles 1 to 9 to reduce neuropathy.
• Additional Treatments: Thromboprophylaxis for VMPT-VT patients.
Outcomes • Primary: Progression-free survival.
• Secondary: Response rate, time to first response, overall survival, incidence of ≥
grade 3 adverse events.
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Notes • Sponsor/Funding: Fondazione Neoplasie Sangue Onlus.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: Palumbo 2014 (updated follow-up).
• KPS = Karnofsky Performance Status.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Unclear risk Not reported. Multi-centre trial, therefore
probably centrally randomised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
International Uniform Response Crite-
ria, overall survival) however independent
blinded outcomes assessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart accounting for all pa-
tients. Acceptable rates of withdrawal/lost
to follow-up
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk Not reported.
GIMEMA-MMY-3006 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 73 centres in Italy
from May 2006 to Apr 2008.
• Overall sample size: N = 480 patients. Experimental arm (VTD: bortezomib,
thalidomide, dexamethasone) = 241 patients. Control Arm (TD: thalidomide,
dexamethasone) = 239 patients.
Participants • Patient Population: Patients with newly diagnosed and untreated symptomatic
multiple myeloma.
• Inclusion Criteria: Age 18-65 years; KPS ≥ 60%; Platelets≥ 70 x 109/L; ANC
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≥ 1 x 109/L; serum creatinine ≤ 176 µmol/L.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; history of venous
thromboembolism; diagnosis of thrombophylic alterations.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • Experimental Arm (VTD): Induction: IV bortezomib 1.3 mg/m2 on days 1, 4,
8, 11 with TD for 3 x 21-day cycles. Consolidation: IV bortezomib 1.3mg/m2 on
Days 1, 8, 15 and 22 with TD for 2 x 35-day cycles.
• Control Arm (TD): Induction: oral thalidomide 100 mg daily first 14 days, 200
mg daily thereafter and dexamethasone 40 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.
Consolidation: oral thalidomide 100 mg daily and oral dexamethasone 40 mg on days
1, 2, 8, 9, 15, 16, 22 and 23.
• Additional Treatments: Double ASCT 3-6 months apart following induction
therapy and stem cell mobilisation.
Outcomes • Primary: Complete response rate plus near complete response after induction.
• Secondary: Complete response rate plus near complete response rate to double
transplantation and consolidation therapy, time to progression or relapse, progression-
free survival, overall survival and safety.
Notes • Sponsor/Funding: Seràgnoli Institute of Haematology at the University of
Bologna. Janssen-Cilag provided bortezomib.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: Cavo 2012 (median follow-up 43 months); Cavo 2012
(abstract only, median follow-up 52 months).
• KPS = Karnofsky Performance Status.
• ANC = Absolute Neutrophil Count.
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Patients were randomised via ’web-based
system’ at central coordinating centre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
the European Group for Blood and Bone
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Marrow Transplant (EBMT) criteria, over-
all survival). Responses monitored by ex-
ternal contract research organisation and
centrally reassessed by central coordinating
team
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart accounting for all pa-
tients. Acceptable rates of withdrawal/lost
to follow-up
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk Not reported.
HOVON-65/GMMG-HD4 Study
Methods • Design: Randomised, open-label, phase III trial conducted in Belgium,
Netherlands and Germany from May 2005 to May 2008.
• Overall sample size: N = 827 patients. Experimental arm (PAD ) = 413 patients.
Control arm (VAD) = 414 patients.
Participants • Patient Population: Patients with newly diagnosed symptomatic multiple
myeloma.
• Inclusion Criteria: Age 18-65 years; Performance Status 0-2.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; serum bilirubin ≥ 30
µmol/L; amino transferases ≥ 2.5 normal level.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • Experimental arm (PAD): Induction chemotherapy with bortezomib,
Adriamycin and dexamethasone (PAD) followed by intensive chemotherapy with
melphalan 200 mg/m2 and ASCT, followed by maintenance therapy with bortezomib
for 2 years. PAD = 3 cycles of IV bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11, IV
doxorubicin 9 mg/m2/day on days 1 to 4, oral dexamethasone 40 mg/day on days 1 to
4, 9 to 12, 17 to 20 every 28 days. Maintenance IV bortezomib = 1.3 mg/m2 every 2
weeks for 2 years.
• Control arm (VAD): Induction chemotherapy with vincristine, Adriamycin and
dexamethasone (VAD) followed by intensive chemotherapy with melphalan 200 mg/m
2 and ASCT, followed by maintenance therapy with thalidomide for 2 years. VAD = 3
cycles of IV vincristine 0.4 mg/day on days 1 to 4, IV doxorubicin 9 mg/m2/day on
days 1 to 4, oral dexamethasone 40 mg/day on days 1 to 4, 9 to 12, 17 to 20 every 28
days. Maintenance oral thalidomide = 50 mg/day for 2 years.
Outcomes • Primary: Progression-free survival.
• Secondary: Response rate; progression-free survival without censoring patients
with ASCT; progression-free survival from last high-dose melphalan; overall survival;
safety; toxicity.
49Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
HOVON-65/GMMG-HD4 Study (Continued)
Notes • Sponsor/Funding: Dutch-Belgian Hemato-Oncology Cooperative Group and
the German Multicenter Myeloma Group (GMMG). Supported by Dutch Cancer
Foundation, German Federal Ministry of Education and Research, Janssen-Cilag-
Ortho Biotech, Novartis, Amgen, Chugai, and Roche.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: Sonneveld 2013 (abstract only, median follow-up 67
months).
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Patients were randomised via ’web-based’
system.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
modified European Group for Blood and
Bone Marrow Transplant (EBMT) crite-
ria, overall survival), however, indepen-
dent/blinded outcomes assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart accounting for all pa-
tients included.
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
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Methods • Design: Randomised, open-label, phase III trial conducted at 89 centres in
France, Belgium and Switzerland from Aug 2005 to Jan 2008.
• Overall sample size: N = 482 patients:
1. Arm A1 (VAD induction + no consolidation) = 121 patients.
2. Arm A2 (VAD induction + DCEP consolidation) = 121 patients.
3. Arm B1 (BD induction + no consolidation) = 121 patients.
4. Arm B2 (BD induction + DCEP consolidation) = 119 patients.
• VAD induction (A1 + A2) = 242 patients.
• BD induction (B1 + B2) = 240 patients.
Participants • Patient Population: Patients with newly diagnosed untreated symptomatic
multiple myeloma.
• Inclusion Criteria: Age ≤ 65 years; Performance Status ≤ 2; adequate renal,
haematologic, and hepatic function.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; HIV positive; uncontrolled
diabetes.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • VAD: 4 cycles of vincristine 0.4 mg/day on days 1 to 4, doxorubicin 9 mg/m2/day
by continuous infusion on days 1 to 4, oral dexamethasone 40 mg/day on days 1 to 4
(all cycles), 9 to 12, 17 to 20 (cycles 1 and 2) every 28 days.
• BD: 4 cycles of IV bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11, oral
dexamethasone 40 mg/day on days 1 to 4 (all cycles), days 9 to 12 (cycles 1 and 2)
every 21 days.
• DCEP: 2 cycles of dexamethasone 40 mg/day on days 1 to 4, cyclophosphamide
400 mg/m2, etoposide 40 mg/m2, cisplatin 15 mg/m2/day by continuous infusion on
days 1 to 4 every 28 days.
• Additional treatments: Bisphosphonates, antibiotics, anti-fungal and anti-viral
therapies according to local practice.
Outcomes • Primary: Post-induction Complete Response/near Complete Response (CR/
nCR) rate.
• Secondary: Post-induction overall response rate; CR/nCR rate with and without
DCEP consolidation; CR/nCR and at least VGPR rates post first transplantation;
proportion of patients requiring second transplantation; safety and toxicity.
Notes • Sponsor/Funding: Investigator-initiated trial.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: None.
• HIV = human immunodeficiency virus.
• CR/nCR = Complete Response/near Complete Response.
• VGPR = Very Good Partial Response.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
51Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
IFM 2005-01 Study (Continued)
Allocation concealment (selection bias) Low risk Patientswere ’centrally randomly assigned’.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
modified European Group for Blood and
BoneMarrow Transplant (EBMT) criteria,
overall survival). Responses confirmed by
independent review committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart accounting for all pa-
tients included. Acceptable rates of with-
drawal
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
IFM 2007-02 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 50 centres in
France from Mar 2008 to Jan 2009.
• Overall sample size: N = 199 patients. Experimental arm (vtD) = 100 patients.
Control arm (VD) = 99 patients.
Participants • Patient Population: Patients with newly diagnosed untreated symptomatic
multiple myeloma.
• Inclusion Criteria: Age ≤ 65 years; Performance Status ≤ 2; adequate renal
function.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; HIV positive; uncontrolled
diabetes; amyloidosis; history of other cancer (except basal cell carcinoma and cervix
cancer in situ).
• Baseline Characteristics: No significant imbalance apparent or reported except
difference in proportion of patients with t(4;14) and/or del (17p) higher in vtD arm
than VD arm.
Interventions • vtD: 4 cycles of IV bortezomib 1.0 mg/m2 on days 1, 4, 8 and 11, oral
thalidomide 100 mg/day and oral dexamethasone 40 mg/day on days 1 to 4 (all cycles),
days 9 to 12 (cycles 1 and 2) every 21 days. In case of < PR after cycle 2, bortezomib
increased to 1.3 mg/m2 and thalidomide to 200 mg/day.
• VD: 4 cycles of IV bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11, oral
dexamethasone 40 mg/day on days 1 to 4 (all cycles), days 9 to 12 (cycles 1 and 2)
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every 21 days.
• Additional treatments: Bisphosphonates, antibiotics and anti-viral therapies
according to local practice.
Outcomes • Primary: Post-induction CR rate.
• Secondary: CR plus VGPR rates after cycle 2, after induction and after ASCT;
overall response rates (≥ PR) after cycle 2, after induction and after ASCT; safety and
toxicity.
Notes • Sponsor/Funding: Investigator-initiated trial by the Intergroupe Francophone du
Myelome (IFM).
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: None.
• CR = Complete Response.
• VGPR = Very Good Partial Response.
• PR = Partial Response.
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Patients were ’centrally randomised’.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
International Myeloma Working Group
UniformCriteria, overall survival). Labora-
tory samples to evaluate response data were
centrally evaluated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart accounting for all pa-
tients included. Acceptable rates of with-
drawal
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
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Methods • Design: Randomised, open-label, phase II trial conducted at 1 centre in US from
October 2006 to September 2007.
• Overall sample size: N = 60 patients. Randomised to 1 of 3 groups (N = 20 per
group).
• Group 1 Control Arm: No bortezomib + Melphalan (Mel) + Ascorbic Acid (AA)
+Arsenic Trioxide (ATO).
• Group 2 Treatment Arm: Bortezomib 1.0 mg/m2 + Mel + AA +ATO.
• Group 3 Treatment Arm: Bortezomib 1.5 mg/m2+ Mel + AA +ATO.
Participants • Patient Population: Patients with newly diagnosed multiple myeloma
undergoing ASCT.
• Inclusion Criteria: Age ≤ 75 years; PS < 2; serum bilirubin < 2 x ULN; SGPT <
4 x ULN.
• Baseline Characteristics: No significant imbalances apparent or reported.
Interventions • Group 1 Control Arm:Mel (100 mg/m2 IV days -4, -3), AA (100 mg/m2 IV
days -9 to -3), ATO (0.25 mg/kg IV days -9 to -3).
• Group 2 Treatment Arm: Bortezomib 1.0 mg/m2 IV days -9, -6, -3 + Mel + AA
+ATO.
• Group 3 Treatment Arm: Bortezomib 1.5 mg/m2 IV days -9, -6, -3 + Mel + AA
+ATO.
• Additional treatments: Supportive care according to established guidelines.
Outcomes • Primary: Complete response, time to grade IV toxicity and death.
• Secondary: Response rate, progression-free survival, overall survival and safety.
Notes • Sponsor/Funding: Sponsored by M.D. Anderson Cancer Center. Part supported
by grant from Cephalon Oncology.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: None.
• PS = Performance Status.
• ULN = Upper Normal Limit.
• SGPT = Serum glutamic pyruvic transaminase.
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
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Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate, overall survival)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients withdrew early (from group 1
and group 3). No lost to follow-up patients
reported
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
MMVAR/IFM 2005-04 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 60 centres in 9
countries in Europe and Israel from Jan 2006 to Jul 2010.
• Overall sample size: N = 269 patients. Experimental Arm A (VTD: bortezomib
+ thalidomide + dexamethasone) = 135 patients. Control Arm (TD: thalidomide +
dexamethasone Alone) = 134 patients.
Participants • Patient Population: Patients with relapsed multiple myeloma following ASCT.
• Inclusion Criteria: KPS > 50%; platelets ≥ 40,000/µL; ANC ≥ 1,000/µL;
creatinine clearance ≥ 30 mL/min.
• Exclusion Criteria: ≥ grade 2 peripheral neuropathy; prior allogeneic SCT.
• Baseline Characteristics: No significant imbalances apparent or reported.
Interventions • Experimental Arm (VTD): IV bortezomib 1.3 mg/m2 on days 1, 4, 8, 11 of 21
day cycle for 8 cycles (6 months), followed by IV bortezomib 1.3 mg/m2 on days 1, 8,
15 and 22 of 42 day cycle for 4 cycles (6 months) with TD. Total duration = 1 year.
• Control Arm (TD): Oral thalidomide 200 mg daily and oral dexamethasone 40
mg on 4 days every 3 weeks. Total duration = 1 year.
Outcomes • Primary: Time to disease progression.
• Secondary: Progression-free survival; overall survival; overall response rate
(complete plus partial); adverse events.
Notes • Sponsor/Funding: European Group for Blood and Marrow Transplantation.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: None.
• KPS = Karnofksy Performance Status.
• ANC = Absolute Neutrophil Count.
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
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MMVAR/IFM 2005-04 Study (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Unclear risk Not specified. Central randomisation most
probably performed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
European Group for Blood and BoneMar-
row Transplant (EBMT) criteria, overall
survival). Independent outcomes assess-
ment not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow chart with all randomised patients ac-
counted for. Low rate of lost to follow-up.
All patients included in intention-to-treat
Analysis
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
MMY-3021 Study
Methods • Design: Randomised, open-label, phase III non-inferiority trial conducted at 53
centres in 10 countries in Europe, Asia and South America from Jul 2008 to Feb 2010.
• Overall sample size: N = 222 patients. 2 : 1 allocation. Experimental arm (SC
bortezomib) = 148 patients. Control arm (IV bortezomib) = 74 patients.
Participants • Patient Population:Multiple myeloma patients with measurable progressive
disease.
• Inclusion Criteria: Age ≥ 18 years; KPS ≥ 70%; 1 to 3 prior lines of therapy;
adequate haematologic, hepatic and renal function.
• Exclusion Criteria: Prior bortezomib therapy; ≥ grade 2 peripheral neuropathy
or neuropathic pain; anti-neoplastic, experimental, corticosteroid (> 10 mg/day
prednisone or equivalent) therapy within 3 weeks of randomisation.
• Baseline Characteristics: No significant imbalance apparent or reported except:
higher number of patients in SC group with KPS < 80%, creatinine clearance < 60
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MMY-3021 Study (Continued)
mL/min and from Eastern Europe; higher number of male patients and patients with
high-risk cytogenetics in IV group.
Interventions • Experimental Arm: Bortezomib 1.3 mg/m2 by SC injection on days 1, 4, 8, 11
of 21-day cycle up to 8 cycles.
• Control Arm: Bortezomib 1.3 mg/m2 by IV infusion on days 1, 4, 8, 11 of 21-
day cycle up to 8 cycles.
• Patients with suboptimal response (< CR, without disease progression) at end of
cycle 4 could additionally receive oral dexamethasone from cycle 5 onwards. Patients
with stable disease or PR as best response at end of cycle 8, evolving steadily to late PR
or CR, respectively, could receive two additional cycles.
• Additional Treatments: Concomitant supportive care therapies allowed except
systemic steroids and anti-neoplastic therapies with anti-myeloma effects.
Bisphosphonates permitted.
Outcomes • Primary: Overall response rate (complete plus partial response) after 4 cycles.
• Secondary: CR, nCR and VGPR rates after 4 cycles; ORR after 8 cycles; time to
response; duration of response; time to progression; progression-free survival; 1-year
overall survival; safety and tolerability; pharmacokinetics and pharmacodynamics.
Notes • Sponsor/Funding: Millennium Pharmaceuticals.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: Arnulf, 2012 (extended follow-up data).
• KPS = Karnofksy Performance Status.
• CR/nCR = Complete Response/near Complete Response.
• VGPR = Very Good Partial Response.
• ORR = Overall Response Rate.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’,
employing a ’computer-generated ran-
domisation schedule’ based on ’permuted
blocks’
Allocation concealment (selection bias) Low risk Central randomisation using an ’interac-
tive voice response system’ (IVRS)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
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MMY-3021 Study (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression by European
Group for Blood and Bone Marrow Trans-
plant (EBMT) criteria, overall survival).
Response data based on central laboratory
analysis and blinded response evaluation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart with all randomised pa-
tients accounted for. No lost to follow-up
patients reported
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
NMSG 15/05 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 23 centres in
Denmark, Estonia, Finland, Iceland, Norway and Sweden from Oct 2005 to Apr 2009.
• Overall sample size: N = 370 patients. Experimental arm (bortezomib
consolidation therapy) = 187 patients. Control arm (No consolidation therapy) = 183
patients.
Participants • Patient Population: Patients with newly diagnosed multiple myeloma following
ASCT.
• Exclusion Criteria: > grade 2 peripheral neuropathy; severe heart disease or heart
failure; history of hypotension; prior exposure to bortezomib.
• Baseline Characteristics: No significant imbalances apparent or reported.
Interventions • Experimental Arm: Consolidation therapy with IV bortezomib 1.3 mg/m2 on
days 1, 4, 8, 11 of 21-day cycle for 2 cycles, followed by IV bortezomib 1.3 mg/m2 on
Days 1, 8, 15 of 28-day cycle for 4 cycles.
• Control Arm: No consolidation therapy.
• Additional Treatments: No steroids permitted except < 50 mg prednisone for 1
week for other medical conditions. Bisphosphonates allowed.
Outcomes • Primary: Progression-free survival.
• Secondary: Response rate; overall survival; health-related quality of life;
tolerability.
Notes • Sponsor/Funding: Nordic Myeloma Study Group.
• Type of Publication (Full Text or abstract only): Full Text.
• Linked to other reports: None.
• ASCT = Autologous Stem Cell Transplant.
Risk of bias
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NMSG 15/05 Study (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Central computer randomisation per-
formed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
European Group for Blood and BoneMar-
row Transplant (EBMT) criteria, overall
survival). Independent outcomes assess-
ment not reported but data monitored
by independent contract research organiza-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear flow chart with all randomised pa-
tients accounted for. No lost to follow-up
reported. All patients included in inten-
tion-to-treat analysis
Selective reporting (reporting bias) Unclear risk Benefits and harms reported however se-
lected adverse events reported (peripheral
neuropathy and neuropathic pain) only.
2 secondary malignancies reported (1 on
treatment arm; 1 on control arm)
Other bias Unclear risk None reported.
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NMSG 17/07 Study
Methods • Design: Randomised, open-label, phase III trial conducted at 29 centres in
Norway, Sweden and Denmark from Oct 2007 to Sep 2010.
• Overall sample size: N = 131 patients. Trial prematurely closed due to low
accrual.
• Experimental arm (bortezomib + dexamethasone) = 64 patients. Control arm
(thalidomide + dexamethasone) = 67 patients.
• Cross-over: Patients offered cross-over to other arm at disease progression: 39
patients received bort-dex after failure on thal-dex, 33 received thal-dex after failure on
bort-dex.
Participants • Patient Population: Patients with refractory multiple myeloma.
• Inclusion Criteria: Any age; refractory to prior melphalan treatment.
• Exclusion Criteria: Former treatment with thalidomide, bortezomib,
lenalidomide; ≥ grade 3 sensory neuropathy; ≥ grade 2 neuropathic pain; platelets <
25 x 109/L; severe co-morbidity.
• Baseline Characteristics: Signficantly more females on control arm (thal-dex);
no prognostic importance on univariate analysis. All other characteristics balanced.
Interventions • Experimental Arm (bort-dex); Bortezomib 1.3 mg/m2 IV on days 1, 4, 8, 11 of
21-day cycle. Dexamethasone 20 mg oral on days 1-2, 4-5, 8-9, 11-12 of 21-day cycle.
• Control Arm (thal-dex): Thalidomide 50 mg oral daily, escalated by 50 mg every
3 weeks to a maximum of 200 mg. Dexamethasone 40 mg oral on days 1 to 4 every 3
weeks.
• Additional Treatments: Anti-thrombotic prophylaxis and acyclovir prophylaxis
used routinely.
Outcomes • Primary: Progression-free survival.
• Secondary: Response rate; duration of response; toxicity; health-related quality of
life; time to next treatment; overall survival.
Notes • Sponsor/Funding: Nordic Myeloma Study Group.
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports: None.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Low risk Central web-based randomisation per-
formed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
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NMSG 17/07 Study (Continued)
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective endpoints measured (e.g. re-
sponse rate and progression according to
International Myeloma Working Group
(IMWG) guidelines, overall survival). In-
dependent outcomes assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart for randomised pa-
tients included. Acceptable rates of with-
drawal, no lost to follow-up patients re-
ported. All patients included in intention-
to-treat analysis
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
VISTA Study
Methods • Design: Randomised, open-label, phase III trial conducted at 151 centres in 22
countries in Europe, North and South America and Asia from Dec 2004 to Sep 2006.
• Overall sample size: N = 682 patients. Experimental arm A (VMP: melphalan +
prednisone + bortezomib) = 344 patients. Control arm (MP: melphalan + prednisone
alone) = 338 patients.
Participants • Patient Population: Newly diagnosed, untreated, symptomatic, measurable
multiple myeloma patients not candidates for high-dose therapy plus stem-cell
transplantation.
• Inclusion Criteria: Age ≥ 65 years; measurable disease.
• Exclusion Criteria: Serum creatinine > 2 mg/dL; ≥ grade 2 peripheral
neuropathy or neuropathic pain.
• Baseline Characteristics: No significant imbalance apparent or reported.
Interventions • Experimental Arm: VMP: Nine 6-weekly cycles of melphalan 9 mg/m2and
prednisone at 60 mg/m2on days 1 to 4 of each cycle with IV bortezomib. 1.3 mg/m2
on Days 1, 4, 8, 11, 22, 25, 29 and 32 during cycles 1 to 4 and on days 1, 8, 22 and 29
during cycles 5 to 9.
• Control Arm: MP: Nine 6-weekly cycles of melphalan 9 mg/m2and prednisone
at 60 mg/m2on days 1 to 4 alone.
• Additional Treatments: Bisphosphonates for patients with myeloma-associated
bone disease.
Outcomes • Primary: Time to disease progression.
• Secondary: Progression-free survival, complete plus partial response rate,
complete response rate, duration of response; time to subsequent myeloma therapy,
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VISTA Study (Continued)
overall survival, adverse events, health-related quality of life.
Notes • Sponsor/Funding: Millennium Pharmaceuticals/Johnson & Johnson
Pharmaceutical Research & Development
• Type of Publication (Full text or abstract only): Full text.
• Linked to other reports:Mateos 2010, San Miguel 2013, Delforge 2013, Spicka
2011.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study design described as ’randomised’.
Allocation concealment (selection bias) Unclear risk Not specified. Central randomisation most
probably performed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study.
Blinding of outcome assessment (detection
bias) for OS
Low risk Low risk of bias for OS.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective endpoints measured (e.g. e.g. re-
sponse rate and progression according to
European Group for Blood and BoneMar-
row Transplant (EBMT) criteria, overall
survival). Response data based on central
laboratory analysis of blood and urine sam-
ples
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed flow chart. Low numbers lost to
follow-up/excluded from analysis
Selective reporting (reporting bias) Low risk Benefits and harms reported.
Other bias Unclear risk None reported.
IV: intravenous
SC: subcutaneous
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chen 2011b Described as a ’retrospective randomised’ study. Small study of 46 patients randomised according to date of
hospitalisation
Goldschmidt 2012 Same dose of bortezomib on same days on both arms (PAD regimen = 28 day cycle and VCD regimen = 21-
day cycle)
Kumar 2012 Same dose/schedule of bortezomib on each arm.
Mateos 2010 Same dose/schedule of bortezomib on each arm.
Niesvisky 2010 Same dose/schedule of bortezomib on each arm.
Orlowski 2007 Same dose/schedule of bortezomib on each arm.
PAD:
VCD:
Characteristics of studies awaiting assessment [ordered by study ID]
Mayo Clinic Study
Methods Design: Randomised, open-label, phase II trial.
Overall sample size: N = 150 patients.
Participants Patients with newly diagnosed multiple myeloma who have completed stem cell transplant
Interventions Arm A (bortezomib). Patients receive bortezomib subcutaneously (SC) on days 1 and 15 of courses 1 to 12 and day
1 of courses 13 to 24
Arm B (bortezomib, cyclophosphamide, dexamethasone). Patients receive bortezomib SC as in Arm A, cyclophos-
phamide orally on days 1 and 15 of courses 1 to12 and day 1 of courses 13 to 24, and dexamethasone orally on days
1 and 15 of courses 1 to 12 and day 1 of courses 13 to 24
Arm C (bortezomib, lenalidomide). Patients receive bortezomib SC as in Arm A and lenalidomide orally on days 1
to 28
Outcomes Primary: Proportion of patients with stringent complete response.
Secondary: Survival time, progression-free survival, adverse events.
Notes Sponsor: Mayo Clinic, US. This study is not eligible for inclusion (same dose/schedule of bortezomib on each arm).
To be verified post-publication for addition to next update of this review
63Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Velcade Consolidation Bone Study
Methods Design: Randomised, open-label, phase II trial.
Overall sample size: N = 106 patients.
Participants Patients with multiple myelomawho have received high-dose chemotherapy and autologous stem cell transplantation
Interventions Experimental arm: Bortezomib 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
Control arm: Observation only.
Outcomes Primary: Change From baseline in Bone Mineral Density (BMD).
Secondary: Progression-free survival, bone markers, skeletal events, appearance of new bone lesions, Karnosfsky
performance status, overall survival
Notes Sponsor: Janssen-Cilag International NV. BMD data published by abstract only (EuropeanHaematology Association
(EHA) Congress, June 2014). To consider eligibility of study for inclusion in future update of review if progression-
free survival and/or overall survival data are published
Characteristics of ongoing studies [ordered by study ID]
CLARION Study
Trial name or title CLARION Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 882 patients.
Participants Transplant-ineligible patients with multiple myeloma.
Interventions Carfilzomib, Melphalan, and Prednisone (CMP) versus Bortezomib, Melphalan, and Prednisone (VMP)
Outcomes • Primary: Progression-free survival.
• Secondary: Overall survival, response rates, health-related quality of life.
Starting date 2013
Contact information Onyx Pharmaceuticals
Notes Study in recruitment phase. November 2017 (final data collection date for primary outcome measure). Last
update on Clinicaltrials.gov April 2015
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Consolidation (61-75 years) Study
Trial name or title CR006127 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 154 patients.
Participants Patients with multiple myeloma aged 61 to 75.
Interventions Bortezomib 1.6 mg/m2 IV on days 1, 8, 15 and 22 of 35-day cycle for 4 cycles as consolidation therapy versus
observation
Outcomes • Primary: Event-free survival.
• Secondary: Best response, response rates.
Starting date 2006
Contact information Janssen-Cilag G.m.b.H
Notes May 2013 (final data collection date for primary outcome measure). Last update on Clinicaltrials.gov March
2015. Contact with company confirmed study not yet published
Consolidation (less than 60 years) Study
Trial name or title CR006124 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 217 patients.
Participants Patients with multiple myeloma aged less than 60 years.
Interventions Bortezomib 1.6 mg/m2 IV on days 1, 8, 15 and 22 of 35-day cycle for 4 cycles as consolidation therapy versus
observation
Outcomes • Primary: Event-free survival.
• Secondary: Best response, response rates.
Starting date 2006
Contact information Janssen-Cilag G.m.b.H
Notes May 2013 (final data collection date for primary outcome measure). Last update on Clinicaltrials.gov March
2015. Contact with company confirmed study not yet published
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E1A11 Study
Trial name or title ECOG E1A11 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 525 patients.
Participants Patients with newly diagnosed symptomatic multiple myeloma.
Interventions Bortezomib, Lenalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone
(CRd) followed by limited or indefinite Lenalidomide maintenance
Outcomes • Primary: Overall survival for maintenance analysis.
• Secondary: Progression-free survival for maintenance analysis, overall survival for induction analysis,
response rates, time to progression, duration of response, adverse events, patient-reported outcomes.
Starting date 2013
Contact information Dr SK Kumar, Eastern Cooperative Oncology Group (ECOG)
Notes May 2016 (final data collection date for primary outcome measure). Last update on Clinicaltrials.gov Septem-
ber 2014
ENDEAVOR Study
Trial name or title ENDEAVOR Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 898 patients.
Participants Patients with relapsed multiple myeloma
Interventions Carfilzomib and Dexamethasone versus Bortezomib and Dexamethasone
Outcomes Primary: Progression-free survival
Starting date 2012
Contact information Onyx Pharmaceuticals
Notes January 2016 (final data collection date for primary outcome measure). Last update on Clinicaltrials.gov
March 2015
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Hackensack University Study
Trial name or title PRO# 1307 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 398 patients.
Participants Patients with multiple myeloma 65 years or older.
Interventions Autologous StemCell Transplantationwith high-doseMelphalan versus high-doseMelphalan andBortezomib
Outcomes • Primary: Progression-free survival.
• Secondary: Overall survival, toxicity, response rates.
Starting date 2010
Contact information Dr M Donato, John Theurer Cancer Center, Hackensack University Medical Center, New Jersey, US
Notes Study open to recruitment. November 2014 (final data collection date for primary outcome measure). Last
update on Clinicaltrials.gov Aug 2014
HOVON 95 Study
Trial name or title HOVON 95 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 1500 patients.
Participants Patients with newly diagnosed multiple myeloma.
Interventions Bortezomib, Melphalan, Prednisone (VMP) With high-dose Melphalan followed by Bortezomib, Lenalido-
mide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance
Outcomes • Primary: Progression-free survival.
• Secondary: Overall survival, toxicity, response rates.
Starting date 2011
Contact information Prof. P Sonneveld, Stichting Hemato-Oncologie voor Volwassenen Nederland
Notes April 2021 (final data collection date for primary outcome measure). Last update on Clinicaltrials.gov March
2015
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King Fasail Hospital Study
Trial name or title 2081-113 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 440 patients.
Participants Patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell
transplant
Interventions Lenalidomide and low dose dexamethasone (LLD) versus bortezomib, lenalidomide and low dose dexam-
ethasone (BLLD) as induction therapy
Outcomes Progression-free survival.
Starting date 2009
Contact information Dr N Chaudri, King Faisal Specialist Hospital & Reseach Center, Riyadh, Saudi Arabia
Notes January 2013 (Final data collection date for primary outcome measure). Recruitment status unknown; last
update on Clinicaltrials.gov Feb 2012
Optimized Retreatment Study
Trial name or title CR018796 Study
Methods • Design: Randomised, open-label, phase III trial.
Overall sample size: N = 80 patients.
Participants Patients with multiple myeloma in first or second relapse.
Interventions • Experimental Arm: Retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles
followed by four 35-day cycles) followed by a second randomisation in a 1:1 ratio to 1 of 2 prolonged
therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or
Group A2: once every other week).
• Control Arm: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles,
followed by posttreatment follow-up every 6 weeks.
Outcomes • Primary: Progression-free survival.
• Secondary: Response rates, time to progression, duration of response, time to next myeloma therapy,
performance status, health-related quality of life.
Starting date 2013
Contact information Janssen-Cilag International NV
Notes January 2016 (final data collection date for primary outcome measure). Last update on Clinicaltrials.gov April
2015
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Subcutaneous Bortezomib Maintenance Study
Trial name or title Subcutaneous bortezomib maintenance Study
Methods • Design: Randomised, open-label, phase II trial.
• Overall sample size: N = 216 patients.
Participants Patients with relapsed and refractory multiple myeloma after salvage with bortezomib-based therapy
Interventions • Experimental arm: SC bortezomib and oral dexamethasone every 2 weeks. Patients randomised in
this group will be observed. At the occurrence of biochemical relapse, 4 cycles of SC bortezomib and oral
dexamethasone weekly will be administered.
• Control arm: Observation only.
Outcomes • Primary: Time to progression.
• Secondary: Response rates, overall survival.
Starting date 2013
Contact information Stichting Hemato-Oncologie voor Volwassenen Nederland.
Notes Study open to recruitment. November 2016 (final data collection date for primary outcome measure). Last
update on Clinicaltrials.gov March 2015
SWOG-S0777 Study
Trial name or title SWOG-S0777 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 756 patients.
Participants Previously untreated multiple myeloma without intent for immediate Autologous Stem Cell Transplant
Interventions Lenalidomide and Low Dose Dexamethasone (LLD) versus Bortezomib, Lenalidomide and Low Dose Dex-
amethasone (BLLD) as induction therapy
Outcomes • Primary: Progression-free survival.
• Secondary: Response rates, overall survival.
Starting date 2008
Contact information Dr BG Durie, Southwest Oncology Group (SWOG).
Notes Follow-up continuing. Last update on Clinicaltrials.gov September 2014
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VCAT Study
Trial name or title CR018751 Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 253 patients.
Participants Patients with multiple myeloma after receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD)
Induction and Autologous Stem Cell Transplant
Interventions Bortezomib Consolidation (With Thalidomide and Prednisolone) versus Thalidomide and Prednisolone
Alone
Outcomes • Primary: Response rates.
• Secondary: Response rates, progression-free survival, disease-free survival, overall survival.
Starting date 2012
Contact information Janssen Scientific Affairs, LLC
Notes October 2015 (Final data collection date for primary outcome measure). Last update on Clinicaltrials.gov
March 2015
Wuerzburg University Hospital Study
Trial name or title DSMM XIV Study
Methods • Design: Randomised, open-label, phase III trial.
• Overall sample size: N = 406 patients.
Participants Patients with newly diagnosed multiple myeloma.
Interventions Lenalidomide, Adriamycin, Dexamethasone (RAD) versus Lenalidomide, Bortezomib, Dexamethasone
(VRD) as induction therapy followed by response-adapted consolidation and lenalidomide maintenance
Outcomes • Primary: Response rates, progression-free survival.
• Secondary: Response rates, overall survival, toxicity, number of hospital days/hospitalisations.
Starting date 2012
Contact information Dr Stefan Knop, Wuerzburg University Hospital.
Notes Study still recruiting. Last update on Clinicaltrials.gov September 2012
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D A T A A N D A N A L Y S E S
Comparison 1. All Studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival 9 4118 Peto Odds Ratio (95% CI) 0.77 [0.69, 0.86]
1.1 Bortezomib versus no
bortezomib (same background
therapy)
4 1586 Peto Odds Ratio (95% CI) 0.77 [0.65, 0.92]
1.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
5 2532 Peto Odds Ratio (95% CI) 0.76 [0.67, 0.88]
2 Progression-Free Survival 9 4344 Peto Odds Ratio (95% CI) 0.67 [0.61, 0.72]
2.1 Bortezomib versus no
bortezomib (same background
therapy)
5 1855 Peto Odds Ratio (95% CI) 0.65 [0.57, 0.74]
2.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
4 2489 Peto Odds Ratio (95% CI) 0.67 [0.61, 0.75]
3 Complete Response Rate 12 4630 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [2.02, 2.73]
3.1 Bortezomib versus no
bortezomib (same background
therapy)
6 2064 Odds Ratio (M-H, Fixed, 95% CI) 2.63 [2.13, 3.24]
3.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
6 2566 Odds Ratio (M-H, Fixed, 95% CI) 2.08 [1.67, 2.58]
4 Overall Response Rate 12 4630 Odds Ratio (M-H, Fixed, 95% CI) 2.62 [2.25, 3.05]
4.1 Bortezomib versus no
bortezomib (same background
therapy)
6 2064 Odds Ratio (M-H, Fixed, 95% CI) 3.45 [2.72, 4.37]
4.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
6 2566 Odds Ratio (M-H, Fixed, 95% CI) 2.17 [1.78, 2.64]
5 Treatment-related death 5 2389 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.43, 1.34]
5.1 Bortezomib versus no
bortezomib (same background
therapy)
2 737 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.30, 2.16]
5.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
3 1652 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.36, 1.48]
6 Adverse Events:
Thrombocytopenia
8 3791 Odds Ratio (M-H, Fixed, 95% CI) 2.05 [1.70, 2.48]
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6.1 Bortezomib versus no
bortezomib (same background
therapy)
3 1196 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [1.13, 2.00]
6.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
5 2595 Odds Ratio (M-H, Fixed, 95% CI) 2.60 [2.01, 3.35]
7 Adverse Events: Neutropenia 8 3791 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [1.10, 1.60]
7.1 Bortezomib versus no
bortezomib (same background
therapy)
3 1196 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.73, 1.24]
7.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
5 2595 Odds Ratio (M-H, Fixed, 95% CI) 1.85 [1.41, 2.41]
8 Adverse Events: Anaemia 6 3404 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.65, 1.00]
8.1 Bortezomib versus no
bortezomib (same background
therapy)
2 939 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.48, 0.94]
8.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
4 2465 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.69, 1.21]
9 Adverse Events:
Nausea/Vomiting
8 3788 Odds Ratio (M-H, Fixed, 95% CI) 2.37 [1.64, 3.42]
9.1 Bortezomib versus no
bortezomib (same background
therapy)
4 1670 Odds Ratio (M-H, Fixed, 95% CI) 4.55 [1.99, 10.42]
9.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
4 2118 Odds Ratio (M-H, Fixed, 95% CI) 1.93 [1.28, 2.93]
10 Adverse Events: Diarrhoea 8 3788 Odds Ratio (M-H, Fixed, 95% CI) 2.44 [1.74, 3.43]
10.1 Bortezomib versus no
bortezomib (same background
therapy)
4 1670 Odds Ratio (M-H, Fixed, 95% CI) 6.24 [2.79, 13.98]
10.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
4 2118 Odds Ratio (M-H, Fixed, 95% CI) 1.80 [1.22, 2.65]
11 Adverse Events: Constipation 8 3788 Odds Ratio (M-H, Fixed, 95% CI) 1.59 [1.14, 2.22]
11.1 Bortezomib versus no
bortezomib (same background
therapy)
4 1670 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [1.04, 3.41]
11.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
4 2118 Odds Ratio (M-H, Fixed, 95% CI) 1.47 [0.98, 2.20]
12 Adverse Events: Peripheral
Neuropathy
10 4636 Odds Ratio (M-H, Fixed, 95% CI) 3.71 [2.92, 4.70]
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12.1 Bortezomib versus no
bortezomib (same background
therapy)
5 2040 Odds Ratio (M-H, Fixed, 95% CI) 5.10 [3.37, 7.72]
12.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
5 2596 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [2.30, 4.14]
13 Adverse Events: Infections (All) 9 4266 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [1.27, 1.79]
13.1 Bortezomib versus no
bortezomib (same background
therapy)
4 1670 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.97, 1.93]
13.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
5 2596 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [1.27, 1.90]
14 Adverse Events: Herpes Zoster
infection
4 1733 Odds Ratio (M-H, Fixed, 95% CI) 1.83 [0.91, 3.67]
14.1 Bortezomib versus no
bortezomib (same background
therapy)
2 939 Odds Ratio (M-H, Fixed, 95% CI) 1.93 [0.74, 5.03]
14.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
2 794 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.62, 4.74]
15 Adverse Events: Cardiac
Disorders
5 2191 Odds Ratio (M-H, Fixed, 95% CI) 1.74 [1.17, 2.58]
15.1 Bortezomib versus no
bortezomib (same background
therapy)
2 736 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.39, 3.52]
15.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
3 1455 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [1.21, 2.81]
16 Adverse Events: Fatigue 5 2926 Odds Ratio (M-H, Fixed, 95% CI) 1.96 [1.35, 2.84]
16.1 Bortezomib versus no
bortezomib (same background
therapy)
2 939 Odds Ratio (M-H, Fixed, 95% CI) 3.30 [1.66, 6.58]
16.2 Bortezomib versus
no bortezomib (different
background therapy or other
agents)
3 1987 Odds Ratio (M-H, Fixed, 95% CI) 1.52 [0.97, 2.38]
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Comparison 2. Subgroup Analyses - Disease Setting
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival 8 4075 Peto Odds Ratio (95% CI) 0.77 [0.70, 0.86]
1.1 Relapsed / Refactory 1 669 Peto Odds Ratio (95% CI) 0.77 [0.61, 0.97]
1.2 Transplant Eligible 5 2213 Peto Odds Ratio (95% CI) 0.86 [0.73, 1.02]
1.3 Transplant Ineligible 2 1193 Peto Odds Ratio (95% CI) 0.70 [0.59, 0.82]
2 Progression Free Survival 11 4344 Peto Odds Ratio (95% CI) 0.67 [0.61, 0.72]
2.1 Relapsed / Refactory 3 938 Peto Odds Ratio (95% CI) 0.57 [0.48, 0.68]
2.2 Transplant Eligible 6 2213 Peto Odds Ratio (95% CI) 0.76 [0.68, 0.85]
2.3 Transplant Ineligible 2 1193 Peto Odds Ratio (95% CI) 0.57 [0.49, 0.67]
3 Complete Response Rate 11 4593 Odds Ratio (M-H, Fixed, 95% CI) 2.38 [2.05, 2.77]
3.1 Relapsed / Refactory 3 998 Odds Ratio (M-H, Fixed, 95% CI) 3.35 [2.06, 5.43]
3.2 Transplant Eligible 6 2424 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [1.56, 2.27]
3.3 Transplant Ineligibile 2 1171 Odds Ratio (M-H, Fixed, 95% CI) 3.69 [2.71, 5.02]
4 Overall Response Rate 11 4593 Odds Ratio (M-H, Fixed, 95% CI) 2.61 [2.24, 3.05]
4.1 Relapsed / Refactory 3 998 Odds Ratio (M-H, Fixed, 95% CI) 2.39 [1.79, 3.20]
4.2 Transplant Eligible 6 2424 Odds Ratio (M-H, Fixed, 95% CI) 2.24 [1.76, 2.85]
4.3 Transplant Ineligibile 2 1171 Odds Ratio (M-H, Fixed, 95% CI) 3.45 [2.63, 4.53]
Comparison 3. Subgroup Analyses - Therapy Setting
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival 5 Peto Odds Ratio (95% CI) Subtotals only
1.1 Induction 3 1783 Peto Odds Ratio (95% CI) 0.81 [0.67, 0.96]
1.2 Consolidation 2 844 Peto Odds Ratio (95% CI) 1.02 [0.71, 1.47]
1.3 Maintenance 2 1338 Peto Odds Ratio (95% CI) 0.76 [0.64, 0.91]
2 Progression Free Survival 5 Peto Odds Ratio (95% CI) Subtotals only
2.1 Induction 3 1783 Peto Odds Ratio (95% CI) 0.75 [0.66, 0.85]
2.2 Consolidation 2 844 Peto Odds Ratio (95% CI) 0.70 [0.58, 0.84]
2.3 Maintenance 2 1338 Peto Odds Ratio (95% CI) 0.70 [0.61, 0.79]
3 Complete Response Rate 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Induction 4 1999 Odds Ratio (M-H, Fixed, 95% CI) 2.04 [1.65, 2.53]
3.2 Consolidation 2 839 Odds Ratio (M-H, Fixed, 95% CI) 1.77 [1.34, 2.33]
3.3 Maintenance 2 1330 Odds Ratio (M-H, Fixed, 95% CI) 1.82 [1.44, 2.31]
4 Overall Response Rate 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Induction 4 1999 Odds Ratio (M-H, Fixed, 95% CI) 2.33 [1.82, 2.99]
4.2 Consolidation 2 839 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [1.20, 4.06]
4.3 Maintenance 2 1330 Odds Ratio (M-H, Fixed, 95% CI) 1.90 [1.38, 2.62]
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Analysis 1.1. Comparison 1 All Studies, Outcome 1 Overall Survival.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 1 Overall Survival
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Bortezomib versus no bortezomib (same background therapy)
GIMEMA-MMY-3006 Study (1) 28/236 32/238 4.5 % 0.76 [ 0.46, 1.26 ]
MD Anderson Study 16/40 6/20 1.4 % 1.17 [ 0.47, 2.90 ]
NMSG 15/05 Study (2) 33/187 27/183 4.3 % 1.39 [ 0.83, 2.34 ]
VISTA Study 176/344 211/338 28.2 % 0.70 [ 0.57, 0.85 ]
Subtotal (95% CI) 807 779 38.5 % 0.77 [ 0.65, 0.92 ]
Heterogeneity: Chi2 = 6.73, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 2.88 (P = 0.0040)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
All India Institute Study 6/22 8/21 Not estimable
APEX Study (3) 0/333 0/336 21.8 % 0.77 [ 0.61, 0.97 ]
GIMEMA-MM-03-05 Study 82/257 111/254 14.4 % 0.70 [ 0.53, 0.93 ]
HOVON-65/GMMG-HD4 Study (4) 0/413 0/414 25.2 % 0.80 [ 0.64, 0.99 ]
IFM 2005-01 Study 40/240 45/242 Not estimable
Subtotal (95% CI) 1265 1267 61.5 % 0.76 [ 0.67, 0.88 ]
Heterogeneity: Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.81 (P = 0.00014)
Total (95% CI) 100.0 % 0.77 [ 0.69, 0.86 ]
Heterogeneity: Chi2 = 7.28, df = 6 (P = 0.30); I2 =18%
Test for overall effect: Z = 4.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
0.5 0.7 1 1.5 2
Favours Bortezomib Favours Control
(1) Estimated
(2) Numbers of events are estimates only
(3) Numbers of events not available
(4) Numbers of events not available
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Analysis 1.2. Comparison 1 All Studies, Outcome 2 Progression-Free Survival.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 2 Progression-Free Survival
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Bortezomib versus no bortezomib (same background therapy)
GIMEMA-MMY-3006 Study (1) 0/236 0/238 8.9 % 0.64 [ 0.49, 0.83 ]
MD Anderson Study 27/40 10/20 1.4 % 1.39 [ 0.71, 2.73 ]
MMVAR/IFM 2005-04 Study (2) 0/135 0/134 7.3 % 0.61 [ 0.45, 0.82 ]
NMSG 15/05 Study (3) 102/187 114/183 8.5 % 0.76 [ 0.58, 1.00 ]
VISTA Study 111/344 172/338 11.1 % 0.56 [ 0.44, 0.71 ]
Subtotal (95% CI) 942 913 37.2 % 0.65 [ 0.57, 0.74 ]
Heterogeneity: Chi2 = 7.86, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 6.45 (P < 0.00001)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study (4) 147/333 196/336 13.8 % 0.55 [ 0.44, 0.68 ]
GIMEMA-MM-03-05 Study 155/257 206/254 14.8 % 0.58 [ 0.47, 0.71 ]
HOVON-65/GMMG-HD4 Study 282/413 303/414 24.5 % 0.78 [ 0.66, 0.92 ]
IFM 2005-01 Study 110/240 128/242 9.7 % 0.79 [ 0.61, 1.01 ]
Subtotal (95% CI) 1243 1246 62.8 % 0.67 [ 0.61, 0.75 ]
Heterogeneity: Chi2 = 10.09, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 7.70 (P < 0.00001)
Total (95% CI) 100.0 % 0.67 [ 0.61, 0.72 ]
Heterogeneity: Chi2 = 18.12, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 10.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Bortezomib Favours Control
(1) Numbers of events not available
(2) Numbers of events not available
(3) Numbers of events are estimates only
(4) Time to progression
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Analysis 1.3. Comparison 1 All Studies, Outcome 3 Complete Response Rate.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 3 Complete Response Rate
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study 45/130 18/127 5.2 % 3.21 [ 1.73, 5.93 ]
GIMEMA-MMY-3006 Study 136/236 97/238 17.9 % 1.98 [ 1.37, 2.85 ]
MD Anderson Study 4/40 4/20 2.1 % 0.44 [ 0.10, 2.00 ]
MMVAR/IFM 2005-04 Study 31/123 16/117 5.4 % 2.13 [ 1.09, 4.14 ]
NMSG 15/05 Study 82/182 64/183 15.3 % 1.52 [ 1.00, 2.32 ]
VISTA Study 102/337 12/331 3.7 % 11.54 [ 6.20, 21.48 ]
Subtotal (95% CI) 1048 1016 49.5 % 2.63 [ 2.13, 3.24 ]
Total events: 400 (Bortezomib), 211 (Control)
Heterogeneity: Chi2 = 36.66, df = 5 (P<0.00001); I2 =86%
Test for overall effect: Z = 9.08 (P < 0.00001)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
All India Institute Study 5/20 5/17 1.8 % 0.80 [ 0.19, 3.42 ]
APEX Study 20/315 2/312 0.8 % 10.51 [ 2.43, 45.35 ]
GIMEMA-MM-03-05 Study 95/250 61/253 16.4 % 1.93 [ 1.31, 2.84 ]
HOVON-65/GMMG-HD4 Study 147/413 99/414 27.8 % 1.76 [ 1.30, 2.38 ]
IFM 2005-01 Study (1) 13/223 3/218 1.2 % 4.44 [ 1.25, 15.79 ]
NMSG 17/07 Study (2) 23/64 9/67 2.5 % 3.62 [ 1.52, 8.61 ]
Subtotal (95% CI) 1285 1281 50.5 % 2.08 [ 1.67, 2.58 ]
Total events: 303 (Bortezomib), 179 (Control)
Heterogeneity: Chi2 = 10.63, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 6.61 (P < 0.00001)
Total (95% CI) 2333 2297 100.0 % 2.35 [ 2.02, 2.73 ]
Total events: 703 (Bortezomib), 390 (Control)
Heterogeneity: Chi2 = 48.46, df = 11 (P<0.00001); I2 =77%
Test for overall effect: Z = 11.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.34, df = 1 (P = 0.13), I2 =57%
0.01 0.1 1 10 100
Favours Control Favours Bortezomib
(1) Denominator is evaluable patients only
(2) VGPR
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Analysis 1.4. Comparison 1 All Studies, Outcome 4 Overall Response Rate.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 4 Overall Response Rate
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study 110/130 79/127 5.8 % 3.34 [ 1.84, 6.07 ]
GIMEMA-MMY-3006 Study 227/236 212/238 3.8 % 3.09 [ 1.42, 6.75 ]
MD Anderson Study 37/40 17/20 0.8 % 2.18 [ 0.40, 11.92 ]
MMVAR/IFM 2005-04 Study 106/123 86/117 5.8 % 2.25 [ 1.17, 4.33 ]
NMSG 15/05 Study 175/182 175/183 3.2 % 1.14 [ 0.41, 3.22 ]
VISTA Study 238/337 115/331 16.2 % 4.52 [ 3.26, 6.25 ]
Subtotal (95% CI) 1048 1016 35.6 % 3.45 [ 2.72, 4.37 ]
Total events: 893 (Bortezomib), 684 (Control)
Heterogeneity: Chi2 = 9.00, df = 5 (P = 0.11); I2 =44%
Test for overall effect: Z = 10.19 (P < 0.00001)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
All India Institute Study 16/20 9/17 0.9 % 3.56 [ 0.83, 15.18 ]
APEX Study 121/315 56/312 16.4 % 2.85 [ 1.97, 4.12 ]
GIMEMA-MM-03-05 Study 222/250 205/253 10.8 % 1.86 [ 1.12, 3.07 ]
HOVON-65/GMMG-HD4 Study 373/413 343/414 15.7 % 1.93 [ 1.28, 2.92 ]
IFM 2005-01 Study (1) 175/223 137/218 14.1 % 2.16 [ 1.41, 3.28 ]
NMSG 17/07 Study 40/64 37/67 6.4 % 1.35 [ 0.67, 2.72 ]
Subtotal (95% CI) 1285 1281 64.4 % 2.17 [ 1.78, 2.64 ]
Total events: 947 (Bortezomib), 787 (Control)
Heterogeneity: Chi2 = 5.01, df = 5 (P = 0.42); I2 =0%
Test for overall effect: Z = 7.65 (P < 0.00001)
Total (95% CI) 2333 2297 100.0 % 2.62 [ 2.25, 3.05 ]
Total events: 1840 (Bortezomib), 1471 (Control)
Heterogeneity: Chi2 = 22.79, df = 11 (P = 0.02); I2 =52%
Test for overall effect: Z = 12.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.63, df = 1 (P = 0.00), I2 =88%
0.01 0.1 1 10 100
Favours Control Favours Bortezomib
(1) Denominator is evaluable patients only
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Analysis 1.5. Comparison 1 All Studies, Outcome 5 Treatment-related death.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 5 Treatment-related death
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
MD Anderson Study 0/40 1/20 7.3 % 0.16 [ 0.01, 4.12 ]
VISTA Study 7/340 7/337 25.5 % 0.99 [ 0.34, 2.86 ]
Subtotal (95% CI) 380 357 32.8 % 0.81 [ 0.30, 2.16 ]
Total events: 7 (Bortezomib), 8 (Control)
Heterogeneity: Chi2 = 1.10, df = 1 (P = 0.30); I2 =9%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 4/331 4/332 14.6 % 1.00 [ 0.25, 4.04 ]
GIMEMA-MM-03-05 Study 9/254 7/257 24.9 % 1.31 [ 0.48, 3.58 ]
IFM 2005-01 Study 0/239 7/239 27.7 % 0.06 [ 0.00, 1.14 ]
Subtotal (95% CI) 824 828 67.2 % 0.73 [ 0.36, 1.48 ]
Total events: 13 (Bortezomib), 18 (Control)
Heterogeneity: Chi2 = 4.25, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 1204 1185 100.0 % 0.76 [ 0.43, 1.34 ]
Total events: 20 (Bortezomib), 26 (Control)
Heterogeneity: Chi2 = 5.27, df = 4 (P = 0.26); I2 =24%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.6. Comparison 1 All Studies, Outcome 6 Adverse Events: Thrombocytopenia.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 6 Adverse Events: Thrombocytopenia
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study 10/130 6/127 3.6 % 1.68 [ 0.59, 4.77 ]
MMVAR/IFM 2005-04 Study 22/133 9/129 4.9 % 2.64 [ 1.17, 5.98 ]
VISTA Study 126/340 102/337 41.5 % 1.36 [ 0.98, 1.87 ]
Subtotal (95% CI) 603 593 50.0 % 1.51 [ 1.13, 2.00 ]
Total events: 158 (Bortezomib), 117 (Control)
Heterogeneity: Chi2 = 2.27, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 2.82 (P = 0.0048)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 97/331 22/332 10.0 % 5.84 [ 3.57, 9.56 ]
GIMEMA-MM-03-05 Study 55/250 50/253 24.9 % 1.15 [ 0.74, 1.76 ]
HOVON-65/GMMG-HD4 Study 41/410 20/410 11.6 % 2.17 [ 1.25, 3.77 ]
IFM 2005-01 Study 7/239 3/239 1.9 % 2.37 [ 0.61, 9.29 ]
NMSG 17/07 Study 22/64 4/67 1.6 % 8.25 [ 2.65, 25.66 ]
Subtotal (95% CI) 1294 1301 50.0 % 2.60 [ 2.01, 3.35 ]
Total events: 222 (Bortezomib), 99 (Control)
Heterogeneity: Chi2 = 28.71, df = 4 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.35 (P < 0.00001)
Total (95% CI) 1897 1894 100.0 % 2.05 [ 1.70, 2.48 ]
Total events: 380 (Bortezomib), 216 (Control)
Heterogeneity: Chi2 = 37.15, df = 7 (P<0.00001); I2 =81%
Test for overall effect: Z = 7.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.84, df = 1 (P = 0.01), I2 =87%
0.01 0.1 1 10 100
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Analysis 1.7. Comparison 1 All Studies, Outcome 7 Adverse Events: Neutropenia.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 7 Adverse Events: Neutropenia
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study 13/130 18/127 8.5 % 0.67 [ 0.31, 1.44 ]
MMVAR/IFM 2005-04 Study 15/133 21/129 9.8 % 0.65 [ 0.32, 1.33 ]
VISTA Study 136/340 128/337 39.9 % 1.09 [ 0.80, 1.48 ]
Subtotal (95% CI) 603 593 58.2 % 0.95 [ 0.73, 1.24 ]
Total events: 164 (Bortezomib), 167 (Control)
Heterogeneity: Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 48/331 4/332 1.8 % 13.91 [ 4.95, 39.05 ]
GIMEMA-MM-03-05 Study 96/250 71/253 22.5 % 1.60 [ 1.10, 2.32 ]
HOVON-65/GMMG-HD4 Study 12/410 4/410 2.0 % 3.06 [ 0.98, 9.57 ]
IFM 2005-01 Study 12/239 24/239 11.8 % 0.47 [ 0.23, 0.97 ]
NMSG 17/07 Study 11/64 9/67 3.8 % 1.34 [ 0.51, 3.48 ]
Subtotal (95% CI) 1294 1301 41.8 % 1.85 [ 1.41, 2.41 ]
Total events: 179 (Bortezomib), 112 (Control)
Heterogeneity: Chi2 = 30.28, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.50 (P < 0.00001)
Total (95% CI) 1897 1894 100.0 % 1.33 [ 1.10, 1.60 ]
Total events: 343 (Bortezomib), 279 (Control)
Heterogeneity: Chi2 = 39.29, df = 7 (P<0.00001); I2 =82%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 11.83, df = 1 (P = 0.00), I2 =92%
0.01 0.1 1 10 100
Favours Bortezomib Favours Control
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Analysis 1.8. Comparison 1 All Studies, Outcome 8 Adverse Events: Anaemia.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 8 Adverse Events: Anaemia
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
MMVAR/IFM 2005-04 Study 10/133 6/129 3.1 % 1.67 [ 0.59, 4.73 ]
VISTA Study 62/340 92/337 41.6 % 0.59 [ 0.41, 0.86 ]
Subtotal (95% CI) 473 466 44.7 % 0.67 [ 0.48, 0.94 ]
Total events: 72 (Bortezomib), 98 (Control)
Heterogeneity: Chi2 = 3.35, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 2.32 (P = 0.021)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 33/331 35/332 17.3 % 0.94 [ 0.57, 1.55 ]
GIMEMA-MM-03-05 Study 25/250 25/253 12.3 % 1.01 [ 0.57, 1.82 ]
HOVON-65/GMMG-HD4 Study 33/410 29/411 14.7 % 1.15 [ 0.69, 1.94 ]
IFM 2005-01 Study 10/239 21/239 11.1 % 0.45 [ 0.21, 0.98 ]
Subtotal (95% CI) 1230 1235 55.3 % 0.92 [ 0.69, 1.21 ]
Total events: 101 (Bortezomib), 110 (Control)
Heterogeneity: Chi2 = 4.04, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 1703 1701 100.0 % 0.80 [ 0.65, 1.00 ]
Total events: 173 (Bortezomib), 208 (Control)
Heterogeneity: Chi2 = 9.45, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Chi2 = 1.94, df = 1 (P = 0.16), I2 =48%
0.01 0.1 1 10 100
Favours Bortezomib Favours Control
82Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 All Studies, Outcome 9 Adverse Events: Nausea/Vomiting.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 9 Adverse Events: Nausea/Vomiting
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study (1) 11/130 3/127 6.9 % 3.82 [ 1.04, 14.04 ]
GIMEMA-MMY-3006 Study (2) 5/236 1/238 2.4 % 5.13 [ 0.59, 44.25 ]
MMVAR/IFM 2005-04 Study (3) 1/133 1/129 2.5 % 0.97 [ 0.06, 15.67 ]
VISTA Study (4) 14/340 2/337 4.8 % 7.19 [ 1.62, 31.90 ]
Subtotal (95% CI) 839 831 16.7 % 4.55 [ 1.99, 10.42 ]
Total events: 31 (Bortezomib), 7 (Control)
Heterogeneity: Chi2 = 1.63, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study (5) 19/331 4/332 9.4 % 4.99 [ 1.68, 14.84 ]
GIMEMA-MM-03-05 Study 2/250 3/253 7.4 % 0.67 [ 0.11, 4.06 ]
HOVON-65/GMMG-HD4 Study (6) 45/410 29/411 64.2 % 1.62 [ 1.00, 2.65 ]
NMSG 17/07 Study 2/64 1/67 2.4 % 2.13 [ 0.19, 24.07 ]
Subtotal (95% CI) 1055 1063 83.3 % 1.93 [ 1.28, 2.93 ]
Total events: 68 (Bortezomib), 37 (Control)
Heterogeneity: Chi2 = 4.74, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 3.12 (P = 0.0018)
Total (95% CI) 1894 1894 100.0 % 2.37 [ 1.64, 3.42 ]
Total events: 99 (Bortezomib), 44 (Control)
Heterogeneity: Chi2 = 9.54, df = 7 (P = 0.22); I2 =27%
Test for overall effect: Z = 4.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.29, df = 1 (P = 0.07), I2 =70%
0.01 0.1 1 10 100
Favours Bortezomib Favours Control
(1) All gastro-intestinal adverse events
(2) All gastro-intestinal adverse events except constipation
(3) All gastro-intestinal adverse events except constipation
(4) Vomiting only
(5) Sum of nausea and vomiting
(6) All gastro-intestinal adverse events
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Analysis 1.10. Comparison 1 All Studies, Outcome 10 Adverse Events: Diarrhoea.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 10 Adverse Events: Diarrhoea
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study (1) 11/130 3/127 6.1 % 3.82 [ 1.04, 14.04 ]
GIMEMA-MMY-3006 Study (2) 5/236 1/238 2.1 % 5.13 [ 0.59, 44.25 ]
MMVAR/IFM 2005-04 Study (3) 1/133 1/129 2.2 % 0.97 [ 0.06, 15.67 ]
VISTA Study 25/340 2/337 4.1 % 13.29 [ 3.12, 56.59 ]
Subtotal (95% CI) 839 831 14.5 % 6.24 [ 2.79, 13.98 ]
Total events: 42 (Bortezomib), 7 (Control)
Heterogeneity: Chi2 = 3.35, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 4.45 (P < 0.00001)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 24/331 6/332 12.1 % 4.25 [ 1.71, 10.53 ]
GIMEMA-MM-03-05 Study 4/250 7/253 15.0 % 0.57 [ 0.17, 1.98 ]
HOVON-65/GMMG-HD4 Study (4) 45/410 29/411 56.3 % 1.62 [ 1.00, 2.65 ]
NMSG 17/07 Study 1/64 1/67 2.1 % 1.05 [ 0.06, 17.11 ]
Subtotal (95% CI) 1055 1063 85.5 % 1.80 [ 1.22, 2.65 ]
Total events: 74 (Bortezomib), 43 (Control)
Heterogeneity: Chi2 = 7.03, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 2.96 (P = 0.0031)
Total (95% CI) 1894 1894 100.0 % 2.44 [ 1.74, 3.43 ]
Total events: 116 (Bortezomib), 50 (Control)
Heterogeneity: Chi2 = 16.31, df = 7 (P = 0.02); I2 =57%
Test for overall effect: Z = 5.13 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.42, df = 1 (P = 0.01), I2 =87%
0.01 0.1 1 10 100
Favours Bortezomib Favours Control
(1) All gastro-intestinal adverse events
(2) All gastro-intestinal adverse events except constipation
(3) All gastro-intestinal adverse events except constipation
(4) All gastro-intestinal adverse events
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Analysis 1.11. Comparison 1 All Studies, Outcome 11 Adverse Events: Constipation.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 11 Adverse Events: Constipation
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study (1) 11/130 3/127 5.0 % 3.82 [ 1.04, 14.04 ]
GIMEMA-MMY-3006 Study 10/236 7/238 12.0 % 1.46 [ 0.55, 3.90 ]
MMVAR/IFM 2005-04 Study 9/133 7/129 11.9 % 1.26 [ 0.46, 3.50 ]
VISTA Study 2/340 0/337 0.9 % 4.99 [ 0.24, 104.23 ]
Subtotal (95% CI) 839 831 29.7 % 1.88 [ 1.04, 3.41 ]
Total events: 32 (Bortezomib), 17 (Control)
Heterogeneity: Chi2 = 2.37, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 7/331 4/332 7.0 % 1.77 [ 0.51, 6.11 ]
GIMEMA-MM-03-05 Study 6/250 5/253 8.7 % 1.22 [ 0.37, 4.05 ]
HOVON-65/GMMG-HD4 Study (2) 45/410 29/411 46.2 % 1.62 [ 1.00, 2.65 ]
NMSG 17/07 Study 3/64 5/67 8.3 % 0.61 [ 0.14, 2.66 ]
Subtotal (95% CI) 1055 1063 70.3 % 1.47 [ 0.98, 2.20 ]
Total events: 61 (Bortezomib), 43 (Control)
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Total (95% CI) 1894 1894 100.0 % 1.59 [ 1.14, 2.22 ]
Total events: 93 (Bortezomib), 60 (Control)
Heterogeneity: Chi2 = 4.36, df = 7 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours Bortezomib Favours Control
(1) All gastro-intestinal adverse events
(2) All gastro-intestinal adverse events
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Analysis 1.12. Comparison 1 All Studies, Outcome 12 Adverse Events: Peripheral Neuropathy.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 12 Adverse Events: Peripheral Neuropathy
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study 17/130 6/127 6.6 % 3.03 [ 1.16, 7.97 ]
GIMEMA-MMY-3006 Study 23/236 5/238 5.6 % 5.03 [ 1.88, 13.47 ]
MMVAR/IFM 2005-04 Study 41/133 18/129 15.7 % 2.75 [ 1.48, 5.10 ]
NMSG 15/05 Study 9/187 2/183 2.4 % 4.58 [ 0.98, 21.47 ]
VISTA Study 44/340 0/337 0.5 % 101.31 [ 6.21, 1652.18 ]
Subtotal (95% CI) 1026 1014 30.8 % 5.10 [ 3.37, 7.72 ]
Total events: 134 (Bortezomib), 31 (Control)
Heterogeneity: Chi2 = 9.37, df = 4 (P = 0.05); I2 =57%
Test for overall effect: Z = 7.72 (P < 0.00001)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 26/331 2/332 2.3 % 14.07 [ 3.31, 59.76 ]
GIMEMA-MM-03-05 Study (1) 27/250 13/253 14.3 % 2.24 [ 1.13, 4.44 ]
HOVON-65/GMMG-HD4 Study 98/410 41/411 38.8 % 2.83 [ 1.91, 4.21 ]
IFM 2005-01 Study 17/239 5/239 5.8 % 3.58 [ 1.30, 9.88 ]
NMSG 17/07 Study (2) 17/64 9/67 8.0 % 2.33 [ 0.95, 5.70 ]
Subtotal (95% CI) 1294 1302 69.2 % 3.09 [ 2.30, 4.14 ]
Total events: 185 (Bortezomib), 70 (Control)
Heterogeneity: Chi2 = 5.71, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 7.52 (P < 0.00001)
Total (95% CI) 2320 2316 100.0 % 3.71 [ 2.92, 4.70 ]
Total events: 319 (Bortezomib), 101 (Control)
Heterogeneity: Chi2 = 15.07, df = 9 (P = 0.09); I2 =40%
Test for overall effect: Z = 10.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.78, df = 1 (P = 0.05), I2 =74%
0.005 0.1 1 10 200
Favours Bortezomib Favours Control
(1) Sensory Neuropathy
(2) Sensory and Motor Neuropathy
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Analysis 1.13. Comparison 1 All Studies, Outcome 13 Adverse Events: Infections (All).
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 13 Adverse Events: Infections (All)
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GEM05MENOS65 Study 27/130 21/127 8.1 % 1.32 [ 0.70, 2.49 ]
GIMEMA-MMY-3006 Study 7/236 11/238 5.1 % 0.63 [ 0.24, 1.66 ]
MMVAR/IFM 2005-04 Study 19/133 9/129 3.7 % 2.22 [ 0.97, 5.11 ]
VISTA Study (1) 33/340 23/337 10.0 % 1.47 [ 0.84, 2.56 ]
Subtotal (95% CI) 839 831 26.9 % 1.37 [ 0.97, 1.93 ]
Total events: 86 (Bortezomib), 64 (Control)
Heterogeneity: Chi2 = 3.84, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 1.80 (P = 0.071)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 43/331 53/332 22.0 % 0.79 [ 0.51, 1.21 ]
GIMEMA-MM-03-05 Study 32/250 23/253 9.5 % 1.47 [ 0.83, 2.59 ]
HOVON-65/GMMG-HD4 Study 170/410 86/411 24.1 % 2.68 [ 1.97, 3.64 ]
IFM 2005-01 Study 21/239 29/239 12.7 % 0.70 [ 0.39, 1.26 ]
NMSG 17/07 Study 25/64 17/67 4.8 % 1.89 [ 0.90, 3.97 ]
Subtotal (95% CI) 1294 1302 73.1 % 1.55 [ 1.27, 1.90 ]
Total events: 291 (Bortezomib), 208 (Control)
Heterogeneity: Chi2 = 28.71, df = 4 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.30 (P = 0.000017)
Total (95% CI) 2133 2133 100.0 % 1.51 [ 1.27, 1.79 ]
Total events: 377 (Bortezomib), 272 (Control)
Heterogeneity: Chi2 = 32.93, df = 8 (P = 0.00006); I2 =76%
Test for overall effect: Z = 4.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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(1) added pneumonia and HZ
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Analysis 1.14. Comparison 1 All Studies, Outcome 14 Adverse Events: Herpes Zoster infection.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 14 Adverse Events: Herpes Zoster infection
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
MMVAR/IFM 2005-04 Study 1/133 0/129 4.1 % 2.93 [ 0.12, 72.64 ]
VISTA Study 11/340 6/337 48.0 % 1.84 [ 0.67, 5.05 ]
Subtotal (95% CI) 473 466 52.1 % 1.93 [ 0.74, 5.03 ]
Total events: 12 (Bortezomib), 6 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 6/331 5/332 40.3 % 1.21 [ 0.36, 4.00 ]
NMSG 17/07 Study 4/64 1/67 7.5 % 4.40 [ 0.48, 40.47 ]
Subtotal (95% CI) 395 399 47.9 % 1.71 [ 0.62, 4.74 ]
Total events: 10 (Bortezomib), 6 (Control)
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 868 865 100.0 % 1.83 [ 0.91, 3.67 ]
Total events: 22 (Bortezomib), 12 (Control)
Heterogeneity: Chi2 = 1.15, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 1.15. Comparison 1 All Studies, Outcome 15 Adverse Events: Cardiac Disorders.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 15 Adverse Events: Cardiac Disorders
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
GIMEMA-MMY-3006 Study 5/236 5/238 12.7 % 1.01 [ 0.29, 3.53 ]
MMVAR/IFM 2005-04 Study 2/133 1/129 2.6 % 1.95 [ 0.18, 21.82 ]
Subtotal (95% CI) 369 367 15.3 % 1.17 [ 0.39, 3.52 ]
Total events: 7 (Bortezomib), 6 (Control)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
GIMEMA-MM-03-05 Study 28/250 14/253 32.1 % 2.15 [ 1.11, 4.20 ]
HOVON-65/GMMG-HD4 Study 32/410 20/411 47.8 % 1.66 [ 0.93, 2.94 ]
NMSG 17/07 Study 3/64 2/67 4.8 % 1.60 [ 0.26, 9.89 ]
Subtotal (95% CI) 724 731 84.7 % 1.84 [ 1.21, 2.81 ]
Total events: 63 (Bortezomib), 36 (Control)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.82 (P = 0.0048)
Total (95% CI) 1093 1098 100.0 % 1.74 [ 1.17, 2.58 ]
Total events: 70 (Bortezomib), 42 (Control)
Heterogeneity: Chi2 = 1.17, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0060)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
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Analysis 1.16. Comparison 1 All Studies, Outcome 16 Adverse Events: Fatigue.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 1 All Studies
Outcome: 16 Adverse Events: Fatigue
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bortezomib versus no bortezomib (same background therapy)
MMVAR/IFM 2005-04 Study 10/133 4/129 9.0 % 2.54 [ 0.78, 8.32 ]
VISTA Study 25/340 7/337 15.6 % 3.74 [ 1.60, 8.77 ]
Subtotal (95% CI) 473 466 24.7 % 3.30 [ 1.66, 6.58 ]
Total events: 35 (Bortezomib), 11 (Control)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00069)
2 Bortezomib versus no bortezomib (different background therapy or other agents)
APEX Study 18/331 12/332 27.2 % 1.53 [ 0.73, 3.24 ]
GIMEMA-MM-03-05 Study 15/250 5/253 11.2 % 3.17 [ 1.13, 8.85 ]
HOVON-65/GMMG-HD4 Study 16/410 16/411 36.9 % 1.00 [ 0.49, 2.03 ]
Subtotal (95% CI) 991 996 75.3 % 1.52 [ 0.97, 2.38 ]
Total events: 49 (Bortezomib), 33 (Control)
Heterogeneity: Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 1.81 (P = 0.070)
Total (95% CI) 1464 1462 100.0 % 1.96 [ 1.35, 2.84 ]
Total events: 84 (Bortezomib), 44 (Control)
Heterogeneity: Chi2 = 7.10, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 3.54 (P = 0.00040)
Test for subgroup differences: Chi2 = 3.43, df = 1 (P = 0.06), I2 =71%
0.01 0.1 1 10 100
Favours Bortezomib Favours Control
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Analysis 2.1. Comparison 2 Subgroup Analyses - Disease Setting, Outcome 1 Overall Survival.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 2 Subgroup Analyses - Disease Setting
Outcome: 1 Overall Survival
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Relapsed / Refactory
APEX Study 0/333 0/336 20.5 % 0.77 [ 0.61, 0.97 ]
Subtotal (95% CI) 333 336 20.5 % 0.77 [ 0.61, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
2 Transplant Eligible
GIMEMA-MMY-3006 Study (1) 28/236 32/238 4.3 % 0.76 [ 0.46, 1.26 ]
HOVON-65/GMMG-HD4 Study (2) 0/413 0/414 23.7 % 0.80 [ 0.64, 0.99 ]
IFM 2005-01 Study 40/240 45/242 6.1 % 0.87 [ 0.57, 1.33 ]
MD Anderson Study 16/40 6/20 1.3 % 1.17 [ 0.47, 2.90 ]
NMSG 15/05 Study (3) 33/187 27/183 4.1 % 1.39 [ 0.83, 2.34 ]
Subtotal (95% CI) 1116 1097 39.4 % 0.86 [ 0.73, 1.02 ]
Heterogeneity: Chi2 = 4.37, df = 4 (P = 0.36); I2 =8%
Test for overall effect: Z = 1.72 (P = 0.085)
3 Transplant Ineligible
GIMEMA-MM-03-05 Study 82/257 111/254 13.5 % 0.70 [ 0.53, 0.93 ]
VISTA Study 176/344 211/338 26.5 % 0.70 [ 0.57, 0.85 ]
Subtotal (95% CI) 601 592 40.1 % 0.70 [ 0.59, 0.82 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000019)
Total (95% CI) 100.0 % 0.77 [ 0.70, 0.86 ]
Heterogeneity: Chi2 = 7.57, df = 7 (P = 0.37); I2 =8%
Test for overall effect: Z = 4.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.20, df = 2 (P = 0.20), I2 =37%
0.5 0.7 1 1.5 2
Favours Bortezomib Favours Control
(1) Estimated
(2) Numbers of events not available
(3) Numbers of events are estimates only
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Analysis 2.2. Comparison 2 Subgroup Analyses - Disease Setting, Outcome 2 Progression Free Survival.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 2 Subgroup Analyses - Disease Setting
Outcome: 2 Progression Free Survival
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Relapsed / Refactory
APEX Study (1) 147/333 196/336 13.8 % 0.55 [ 0.44, 0.68 ]
MMVAR/IFM 2005-04 Study (2) 0/135 0/134 7.3 % 0.61 [ 0.45, 0.82 ]
NMSG 17/07 Study 0/0 0/0 Not estimable
Subtotal (95% CI) 468 470 21.1 % 0.57 [ 0.48, 0.68 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 6.37 (P < 0.00001)
2 Transplant Eligible
GEM05MENOS65 Study 0/0 0/0 Not estimable
GIMEMA-MMY-3006 Study (3) 0/236 0/238 8.9 % 0.64 [ 0.49, 0.83 ]
HOVON-65/GMMG-HD4 Study 282/413 303/414 24.5 % 0.78 [ 0.66, 0.92 ]
IFM 2005-01 Study 110/240 128/242 9.7 % 0.79 [ 0.61, 1.01 ]
MD Anderson Study 27/40 10/20 1.4 % 1.39 [ 0.71, 2.73 ]
NMSG 15/05 Study (4) 102/187 114/183 8.5 % 0.76 [ 0.58, 1.00 ]
Subtotal (95% CI) 1116 1097 53.0 % 0.76 [ 0.68, 0.85 ]
Heterogeneity: Chi2 = 4.81, df = 4 (P = 0.31); I2 =17%
Test for overall effect: Z = 4.84 (P < 0.00001)
3 Transplant Ineligible
GIMEMA-MM-03-05 Study 155/257 206/254 14.8 % 0.58 [ 0.47, 0.71 ]
VISTA Study 111/344 172/338 11.1 % 0.56 [ 0.44, 0.71 ]
Subtotal (95% CI) 601 592 25.9 % 0.57 [ 0.49, 0.67 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 7.05 (P < 0.00001)
Total (95% CI) 100.0 % 0.67 [ 0.61, 0.72 ]
Heterogeneity: Chi2 = 18.12, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 10.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.94, df = 2 (P = 0.00), I2 =85%
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Analysis 2.3. Comparison 2 Subgroup Analyses - Disease Setting, Outcome 3 Complete Response Rate.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 2 Subgroup Analyses - Disease Setting
Outcome: 3 Complete Response Rate
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Relapsed / Refactory
APEX Study 20/315 2/312 0.8 % 10.51 [ 2.43, 45.35 ]
MMVAR/IFM 2005-04 Study 31/123 16/117 5.5 % 2.13 [ 1.09, 4.14 ]
NMSG 17/07 Study (1) 23/64 9/67 2.5 % 3.62 [ 1.52, 8.61 ]
Subtotal (95% CI) 502 496 8.8 % 3.35 [ 2.06, 5.43 ]
Total events: 74 (Bortezomib), 27 (Control)
Heterogeneity: Chi2 = 4.16, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 4.89 (P < 0.00001)
2 Transplant Eligible
GEM05MENOS65 Study 45/130 18/127 5.3 % 3.21 [ 1.73, 5.93 ]
GIMEMA-MMY-3006 Study 136/236 97/238 18.2 % 1.98 [ 1.37, 2.85 ]
HOVON-65/GMMG-HD4 Study 147/413 99/414 28.3 % 1.76 [ 1.30, 2.38 ]
IFM 2005-01 Study (2) 13/223 3/218 1.3 % 4.44 [ 1.25, 15.79 ]
MD Anderson Study 4/40 4/20 2.1 % 0.44 [ 0.10, 2.00 ]
NMSG 15/05 Study 82/182 64/183 15.6 % 1.52 [ 1.00, 2.32 ]
Subtotal (95% CI) 1224 1200 70.8 % 1.88 [ 1.56, 2.27 ]
Total events: 427 (Bortezomib), 285 (Control)
Heterogeneity: Chi2 = 9.38, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 6.56 (P < 0.00001)
3 Transplant Ineligibile
GIMEMA-MM-03-05 Study 95/250 61/253 16.7 % 1.93 [ 1.31, 2.84 ]
VISTA Study 102/337 12/331 3.8 % 11.54 [ 6.20, 21.48 ]
Subtotal (95% CI) 587 584 20.5 % 3.69 [ 2.71, 5.02 ]
Total events: 197 (Bortezomib), 73 (Control)
Heterogeneity: Chi2 = 23.84, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 8.32 (P < 0.00001)
Total (95% CI) 2313 2280 100.0 % 2.38 [ 2.05, 2.77 ]
Total events: 698 (Bortezomib), 385 (Control)
Heterogeneity: Chi2 = 46.61, df = 10 (P<0.00001); I2 =79%
Test for overall effect: Z = 11.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.71, df = 2 (P = 0.00), I2 =87%
0.01 0.1 1 10 100
Favours Control Favours Bortezomib
93Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) VGPR
(2) Denominator is evaluable patients only
Analysis 2.4. Comparison 2 Subgroup Analyses - Disease Setting, Outcome 4 Overall Response Rate.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 2 Subgroup Analyses - Disease Setting
Outcome: 4 Overall Response Rate
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Relapsed / Refactory
APEX Study 121/315 56/312 16.6 % 2.85 [ 1.97, 4.12 ]
MMVAR/IFM 2005-04 Study 106/123 86/117 5.8 % 2.25 [ 1.17, 4.33 ]
NMSG 17/07 Study 40/64 37/67 6.5 % 1.35 [ 0.67, 2.72 ]
Subtotal (95% CI) 502 496 28.9 % 2.39 [ 1.79, 3.20 ]
Total events: 267 (Bortezomib), 179 (Control)
Heterogeneity: Chi2 = 3.48, df = 2 (P = 0.18); I2 =43%
Test for overall effect: Z = 5.90 (P < 0.00001)
2 Transplant Eligible
GEM05MENOS65 Study 110/130 79/127 5.9 % 3.34 [ 1.84, 6.07 ]
GIMEMA-MMY-3006 Study 227/236 212/238 3.9 % 3.09 [ 1.42, 6.75 ]
HOVON-65/GMMG-HD4 Study 373/413 343/414 15.9 % 1.93 [ 1.28, 2.92 ]
IFM 2005-01 Study (1) 175/223 137/218 14.3 % 2.16 [ 1.41, 3.28 ]
MD Anderson Study 37/40 17/20 0.8 % 2.18 [ 0.40, 11.92 ]
NMSG 15/05 Study 175/182 175/183 3.2 % 1.14 [ 0.41, 3.22 ]
Subtotal (95% CI) 1224 1200 43.9 % 2.24 [ 1.76, 2.85 ]
Total events: 1097 (Bortezomib), 963 (Control)
Heterogeneity: Chi2 = 4.54, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 6.59 (P < 0.00001)
3 Transplant Ineligibile
GIMEMA-MM-03-05 Study 222/250 205/253 10.9 % 1.86 [ 1.12, 3.07 ]
VISTA Study 238/337 115/331 16.3 % 4.52 [ 3.26, 6.25 ]
Subtotal (95% CI) 587 584 27.2 % 3.45 [ 2.63, 4.53 ]
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(Continued . . . )
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(. . . Continued)
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 460 (Bortezomib), 320 (Control)
Heterogeneity: Chi2 = 8.45, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 8.92 (P < 0.00001)
Total (95% CI) 2313 2280 100.0 % 2.61 [ 2.24, 3.05 ]
Total events: 1824 (Bortezomib), 1462 (Control)
Heterogeneity: Chi2 = 22.62, df = 10 (P = 0.01); I2 =56%
Test for overall effect: Z = 12.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.92, df = 2 (P = 0.05), I2 =66%
0.01 0.1 1 10 100
Favours Control Favours Bortezomib
(1) Denominator is evaluable patients only
Analysis 3.1. Comparison 3 Subgroup Analyses - Therapy Setting, Outcome 1 Overall Survival.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 3 Subgroup Analyses - Therapy Setting
Outcome: 1 Overall Survival
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Induction
GIMEMA-MMY-3006 Study (1) 28/236 32/238 12.5 % 0.76 [ 0.46, 1.26 ]
HOVON-65/GMMG-HD4 Study (2) 0/413 0/414 69.7 % 0.80 [ 0.64, 0.99 ]
IFM 2005-01 Study 40/240 45/242 17.8 % 0.87 [ 0.57, 1.33 ]
Subtotal (95% CI) 889 894 100.0 % 0.81 [ 0.67, 0.96 ]
Heterogeneity: Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Consolidation
GIMEMA-MMY-3006 Study (3) 28/236 32/238 51.2 % 0.76 [ 0.46, 1.26 ]
NMSG 15/05 Study (4) 33/187 27/183 48.8 % 1.39 [ 0.83, 2.34 ]
Subtotal (95% CI) 423 421 100.0 % 1.02 [ 0.71, 1.47 ]
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Heterogeneity: Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.11 (P = 0.91)
3 Maintenance
GIMEMA-MM-03-05 Study 82/257 111/254 36.3 % 0.70 [ 0.53, 0.93 ]
HOVON-65/GMMG-HD4 Study (5) 0/413 0/414 63.7 % 0.80 [ 0.64, 0.99 ]
Subtotal (95% CI) 670 668 100.0 % 0.76 [ 0.64, 0.91 ]
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.10 (P = 0.0020)
Test for subgroup differences: Chi2 = 2.02, df = 2 (P = 0.36), I2 =1%
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(1) Estimated
(2) Numbers of events not available
(3) Estimated
(4) Numbers of events are estimates only
(5) Numbers of events not available
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Analysis 3.2. Comparison 3 Subgroup Analyses - Therapy Setting, Outcome 2 Progression Free Survival.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 3 Subgroup Analyses - Therapy Setting
Outcome: 2 Progression Free Survival
Study or subgroup Bortezomib Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Induction
GIMEMA-MMY-3006 Study (1) 0/236 0/238 20.7 % 0.64 [ 0.49, 0.83 ]
HOVON-65/GMMG-HD4 Study 282/413 303/414 56.7 % 0.78 [ 0.66, 0.92 ]
IFM 2005-01 Study 110/240 128/242 22.5 % 0.79 [ 0.61, 1.01 ]
Subtotal (95% CI) 889 894 100.0 % 0.75 [ 0.66, 0.85 ]
Heterogeneity: Chi2 = 1.73, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.66 (P < 0.00001)
2 Consolidation
GIMEMA-MMY-3006 Study (2) 0/236 0/238 51.2 % 0.64 [ 0.49, 0.83 ]
NMSG 15/05 Study (3) 102/187 114/183 48.8 % 0.76 [ 0.58, 1.00 ]
Subtotal (95% CI) 423 421 100.0 % 0.70 [ 0.58, 0.84 ]
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00019)
3 Maintenance
GIMEMA-MM-03-05 Study 155/257 206/254 37.7 % 0.58 [ 0.47, 0.71 ]
HOVON-65/GMMG-HD4 Study 282/413 303/414 62.3 % 0.78 [ 0.66, 0.92 ]
Subtotal (95% CI) 670 668 100.0 % 0.70 [ 0.61, 0.79 ]
Heterogeneity: Chi2 = 4.94, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.80, df = 2 (P = 0.67), I2 =0.0%
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Analysis 3.3. Comparison 3 Subgroup Analyses - Therapy Setting, Outcome 3 Complete Response Rate.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 3 Subgroup Analyses - Therapy Setting
Outcome: 3 Complete Response Rate
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Induction
GEM05MENOS65 Study 45/130 18/127 10.0 % 3.21 [ 1.73, 5.93 ]
GIMEMA-MMY-3006 Study 136/236 97/238 34.3 % 1.98 [ 1.37, 2.85 ]
HOVON-65/GMMG-HD4 Study 147/413 99/414 53.3 % 1.76 [ 1.30, 2.38 ]
IFM 2005-01 Study (1) 13/223 3/218 2.4 % 4.44 [ 1.25, 15.79 ]
Subtotal (95% CI) 1002 997 100.0 % 2.04 [ 1.65, 2.53 ]
Total events: 341 (Bortezomib), 217 (Control)
Heterogeneity: Chi2 = 4.46, df = 3 (P = 0.22); I2 =33%
Test for overall effect: Z = 6.55 (P < 0.00001)
2 Consolidation
GIMEMA-MMY-3006 Study 136/236 97/238 53.9 % 1.98 [ 1.37, 2.85 ]
NMSG 15/05 Study 82/182 64/183 46.1 % 1.52 [ 1.00, 2.32 ]
Subtotal (95% CI) 418 421 100.0 % 1.77 [ 1.34, 2.33 ]
Total events: 218 (Bortezomib), 161 (Control)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.05 (P = 0.000051)
3 Maintenance
GIMEMA-MM-03-05 Study 95/250 61/253 37.1 % 1.93 [ 1.31, 2.84 ]
HOVON-65/GMMG-HD4 Study 147/413 99/414 62.9 % 1.76 [ 1.30, 2.38 ]
Subtotal (95% CI) 663 667 100.0 % 1.82 [ 1.44, 2.31 ]
Total events: 242 (Bortezomib), 160 (Control)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 4.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.82, df = 2 (P = 0.66), I2 =0.0%
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98Bortezomib for the treatment of multiple myeloma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Subgroup Analyses - Therapy Setting, Outcome 4 Overall Response Rate.
Review: Bortezomib for the treatment of multiple myeloma
Comparison: 3 Subgroup Analyses - Therapy Setting
Outcome: 4 Overall Response Rate
Study or subgroup Bortezomib Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Induction
GEM05MENOS65 Study 110/130 79/127 14.8 % 3.34 [ 1.84, 6.07 ]
GIMEMA-MMY-3006 Study 227/236 212/238 9.7 % 3.09 [ 1.42, 6.75 ]
HOVON-65/GMMG-HD4 Study 373/413 343/414 39.8 % 1.93 [ 1.28, 2.92 ]
IFM 2005-01 Study (1) 175/223 137/218 35.8 % 2.16 [ 1.41, 3.28 ]
Subtotal (95% CI) 1002 997 100.0 % 2.33 [ 1.82, 2.99 ]
Total events: 885 (Bortezomib), 771 (Control)
Heterogeneity: Chi2 = 2.84, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 6.64 (P < 0.00001)
2 Consolidation
GIMEMA-MMY-3006 Study 227/236 212/238 54.5 % 3.09 [ 1.42, 6.75 ]
NMSG 15/05 Study 175/182 175/183 45.5 % 1.14 [ 0.41, 3.22 ]
Subtotal (95% CI) 418 421 100.0 % 2.21 [ 1.20, 4.06 ]
Total events: 402 (Bortezomib), 387 (Control)
Heterogeneity: Chi2 = 2.27, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 2.54 (P = 0.011)
3 Maintenance
GIMEMA-MM-03-05 Study 222/250 205/253 40.8 % 1.86 [ 1.12, 3.07 ]
HOVON-65/GMMG-HD4 Study 373/413 343/414 59.2 % 1.93 [ 1.28, 2.92 ]
Subtotal (95% CI) 663 667 100.0 % 1.90 [ 1.38, 2.62 ]
Total events: 595 (Bortezomib), 548 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000084)
Test for subgroup differences: Chi2 = 0.98, df = 2 (P = 0.61), I2 =0.0%
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(1) Denominator is evaluable patients only
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A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials search strategy
ID Search
1 MeSH descriptor: [Multiple Myeloma] explode all trees
2 myelom*
3 MeSH descriptor: [Plasmacytoma] explode all trees
4 plasm*cytom*
5 plasmozytom*
6 plasm* cell myelom*
7 myelomatosis
8 MeSH descriptor: [Leukemia, Plasma Cell] explode all trees
9 (plasma* near/3 neoplas*)
10 kahler*
11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
12 (proteasom* near/2 inhibitor*)
13 bortezomib*
14 proscript*
15 (PS-341* or PS341*)
16 (LDP-341* or LDP341* or MLN-341* or MLN341* or MG-341* or MG341*)
17 velcad*
18 #12 or #13 or #14 or #15 or #16 or #17
19 #11 and #18
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Appendix 2. MEDLINE search strategy
ID Search
1 exp MULTIPLE MYELOMA/
2 myelom$.tw,kf,ot.
3 exp PLASMACYTOMA/
4 plasm?cytom$.tw,kf,ot.
5 plasmozytom$.tw,kf,ot.
6 plasm$ cell myelom$.tw,kf,ot.
7 myelomatosis.tw,kf,ot.
8 LEUKEMIA, PLASMA CELL/
9 (plasma$ adj3 neoplas$).tw,kf,ot.
10 kahler.tw,kf,ot.
11 or/1-10
12 (proteasom$ adj2 inhibitor$).tw,kf,ot.
13 bortezomib$.tw,kf,ot,nm.
14 proscript$.tw,kf,nm,ot.
15 (PS-341 or PS341).tw,kf,nm,ot.
16 (LDP-341 or LDP341 or MLN-341 or MLN341 or MG-341 or MG341).tw,kf,nm,ot
17 velcad$.tw,kf,ot.
18 or/12-17
19 11 and 18
20 randomized controlled trial.pt.
21 controlled clinical trial.pt.
22 randomi?ed.ab.
23 placebo.ab.
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(Continued)
24 clinical trials as topic.sh.
25 randomly.ab.
26 trial.ti.
27 or/20-26
28 humans.sh.
29 27 and 28
30 19 and 29
Appendix 3. EMBASE search strategy
ID Search
1 randomization/exp
2 (factorial AND design)
3 (crossover AND procedure/exp)
4 placebo/exp
5 (double AND blind/exp AND procedure/exp)
6 (single AND blind/exp AND procedure/exp)
7 assign*
8 allocat*
9 volunteer*
10 (randomized AND controlled AND trial)
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 (multiple AND myeloma/exp)
13 myelom*
14 plasmacytoma/exp
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(Continued)
15 (plasm* AND cell/exp AND myelom*)
16 (plasma/exp AND cell/exp AND leukemia/exp)
17 (plasma* NEAR/3 neoplas*)
18 12 or 13 or 14 or 15 or 16 or 17
19 (proteasome/exp AND inhibitor)
20 bortezomib/exp
21 velcade/exp
22 velcad*
23 PS 341/exp OR PS341/exp
24 LDP 341/exp OR LDP341/exp or MLN 341/exp OR MLN341/exp OR MG 341/exp OR MG341/exp
25 19 or 20 or 21 or 22 or 23 or 24
26 11 and 18 and 25
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We edited the background section.
We combined two of the comparison groups in themeta-analysis (studies of bortezomib versus no bortezomibwith different background
therapy in each arm and studies of bortezomib versus other agents(s)) as these studies included complex combination regimens/therapies,
with some studies considered as belonging to either comparison.
We planned to only analyse time to progression (TTP) separately, if it were defined differently from progression-free survival (PFS). We
identified four trials in the meta-analysis that measured TTP as an outcome (VISTA Study, GIMEMA-MMY-3006 Study, MMVAR/
IFM 2005-04 Study and APEX Study). We were able to extract and analyse PFS data for the VISTA Study, GIMEMA-MMY-3006
Study and MMVAR/IFM 2005-04 Study, while in the case of the APEX Study, we included TTP data as PFS data were not available.
We therefore did not analyse TTP separately.
We extracted grade three or four adverse events only and not all grades.
We did not perform sensitivity analysis to exclude trials that were overall at high risk of bias, because all trials were considered to be
overall at low to moderate risk of bias.
The number of subgroups were reduced and simplified for the review compared to that outlined in the protocol into twomain categories:
clinical setting and therapy setting as these settings/subgroups were considered to be more clinically relevant and reflected the trial
settings much more accurately of the studies included in this review. We performed subgroup analyses on clinical outcomes only: overall
survival (OS), PFS, complete response rate (CRR) and overall response rate (ORR). We did not analyse age as a subgroup as each trial
enrolled a population with an age range and we deemed it more clinically relevant to analyse trials of transplant eligible versus ineligible
populations.
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